

A



**UTILITY PATENT APPLICATION
UNDER 37 CFR 1.53(b)**



HONORABLE COMMISSIONER OF
PATENTS AND TRADEMARKS
Washington D.C. 20231

Case Docket No. 114205.1200

Sir:

Transmitted herewith for filing is the patent application of:

INVENTOR: Denise R. COOPER and Niketa A. PATEL
FOR: GLUCOSE REGULATED mRNA INSTABILITY ELEMENT

Enclosed are:

- ☒ 124 pages of specification, claims, abstract
- ☐ Declaration & Power of Attorney
- ☐ Priority Claimed
- ☐ Certified copy of _____
- ☒ 46 formal drawings
- ☐ An assignment of the invention to _____
and the assignment recordation fee
- ☒ Return Receipt Postcard
- ☐ Information Disclosure Statement, Form PTO-1449
- ☐ Copies of IDS Citations
- ☐

The filing fee has been calculated as shown below:

(1) FOR	(2) NO. FILED	(3) NO. EXTRA	(4) RATE	(5) AMOUNT
TOTAL CLAIMS	25	-20	5	x \$18.00 = \$90.00
INDEPENDENT CLAIMS	4	-3	1	x \$78.00 = 78.00
MULTIPLE DEPENDENT CLAIM(S) (If applicable)			+ \$260.00 =	00.00
			BASIC FEE	\$ 760.00
Total of above calculations				= \$928.00
<input type="checkbox"/> Assignment & Recording Fee				\$ <u>00</u>

Docket No.: 114205.1200

TOTAL FEE

\$928.00

- ☐ Please charge my Deposit Account No. 50-0436 in the amount of \$928.00. A duplicate copy of this sheet is enclosed.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0436. A duplicate copy is enclosed.
- ☐ Any additional filing fees required under 37 CFR 1.16.
- ☐ The Commissioner is hereby authorized to charge payment of following fees during the pendency of this application or credit any overpayment to Deposit Account No. 50-0436. A duplicate copy of this sheet is enclosed.
- ☐ Any patent application processing fees under 37 CFR 1.17.
- ☐ Any filing fees under 37 CFR 1.16 for presentation of extra claims.
- ☐ Address all future communications to: (May only be completed by applicant, or attorney or agent of record)

Respectfully submitted,

PEPPER, HAMILTON LLP



Gilberto M. Villacorta, Ph.D.
Registration No. 34,038

by Corinne Pouliquen
Registration No. 35,753

600 Fourteenth Street, N.W.
Washington, D.C. 20005-2004
(202) 220-1200 GMV:CMP:cgm
November 8, 1999
DC #132851 v1 (2%\$B011.WPD)

**INTRODUCTION OF A GLUCOSE-REGULATED INSTABILITY
ELEMENT VIA ALTERNATIVE EXON INCLUSION OF PKC β II mRNA IN
VASCULAR SMOOTH MUSCLE CELLS**

INTRODUCTION

Multicellular eukaryotic organisms are capable of responding to extracellular signals to regulate or accentuate gene expression through the process of signal transduction. A large number of the components of the signal transduction pathway comprise of proteins that are covalently modified by ligands such as hormones, growth factors, cytokines or second messengers like cAMP, Ca²⁺, diacylglycerol, inositol-3-phosphate and others. This results in the induction of a cascade leading to gene expression in which activation of kinases that phosphorylate tyrosine or serine/threonine residues play central roles. Prominent targets of second messengers are the cAMP-dependent protein kinase A (PKA) and the Ca²⁺/phospholipid-activated protein kinase C (PKC). The protein kinase C cascade includes several enzymes that are sequentially phosphorylated in response to external stimuli. PKC established its role in signal transduction when it was demonstrated that diacylglycerol, a product of hormone stimulated phosphatidylinositol hydrolysis, was an activator of the enzyme. Multiple lipid pathways contribute to the production of diacylglycerol, the second messenger for PKC. Phorbol esters, which are potent tumor promoters, activate PKC and this discovery led to further excitement in the field (see for example, Nishizuka, 1995, pp.484-496; Nishizuka, 1992, pp.607-614).

Protein Kinase C

Biological role

Protein kinase C modulates diverse cellular functions such as cell cycle progression and differentiation, apoptosis, and tumor promotion (Nishizuka, 1986, pp.305-312). PKC regulates gene expression via transcription through the activation of *cis*-elements. It is a mediator of immune responses, hormone secretion and receptor desensitization. Many of these roles are mediated by accentuating membrane structure events. PKC phosphorylates serine or threonine residues at basic sequences with the motif xRxxS/TxRx. Thus histones H1 and H3, and protamine, are efficient substrates for PKC. In addition to catalyzing phosphorylation reactions, PKC autophosphorylates *in vitro* (on residues Thr-641 and Ser-660 in PKC β II) by an intramolecular mechanism and this may play a role in its proteolytic activation and degradation.

Together with the fact that activation of PKC isozymes is associated with altered gene expression and its presence in the nucleus, it was expected that PKC could phosphorylate some transcription factors and thereby regulate gene expression. PKC phosphorylates CREB, the cAMP-responsive element-binding protein and as a result CRE binding is enhanced. NF- κ B, in the cytosol of resting cells, is in a complex with I- κ B. On PKC activation, by phorbol esters, the inhibitory complex dissociates and NF- κ B translocates into the nucleus as an active transcription factor. C-jun, a phorbol ester-responsive transcription factor, is also regulated by PKC. Vitamin D₃ receptor, a member of the steroid/thyroid hormone family, binds to vitamin D₃ and associates with its DNA element thereby altering gene transcription. PKC β phosphorylates the vitamin D₃

receptor, and inhibits transcriptional activation by vitamin D₃. TLS/FUS, a DNA-binding nuclear protein, is a regulator of BCR/ABL-mediated leukemogenesis (Perrotti *et al.*, 1998, pp.4442-4455). PKCβII phosphorylates TLS/FUS and regulates its DNA-binding activity in the nucleus.

History

Historically, Nishizuka *et al* discovered protein kinase C in rat brain as the proenzyme for a histone protein kinase (see, for example Takai *et al.*, 1977, pp.7603-7609). This protein kinase M (PKM) was generated as a result of partial proteolysis by trypsin or a calcium-dependent protease. From biochemical studies, it was soon established that the proenzyme, PKC, exhibited kinase activity upon membrane association. It is now well established that protein kinase C, a family of serine/threonine kinase isozymes, translocates from the cytosol to another intracellular compartment like the membrane or nucleus in response to stimuli from neurotransmitters, hormones and growth factors. Most PKCs are activated by phosphatidylserine, an acidic lipid located on the cytoplasmic side of the membrane, diacylglycerol and phorbol esters. Some PKC family members also require Ca²⁺ and other lipid second messengers for optimal activity.

Protein kinase C isozyme family

Biochemical and molecular cloning analysis of protein kinase C revealed a large family of isozymes exhibiting individual characteristics and functions and tissue specific distribution. Protein kinase C isozymes comprise a single polypeptide chain with a 20-70 kDa amino-terminal regulatory domain and an approximately 45 kDa kinase domain at the carboxy-terminus. The PKC isozymes, to date, can be categorized into at least three

groups based on their homology and sensitivity to their cofactors (Table 1). The earliest discovered PKC isozymes are the members of conventional or classical PKC (cPKC) and include PKC α , β I, β II (alternatively spliced variants of β) and γ . This class of isozymes is activated by diacylglycerol, phosphatidylserine, phorbol esters and Ca^{2+} . The novel PKC (nPKC) subfamily of isozymes include PKC δ , ϵ , η , and θ and are calcium-independent. The least understood are the atypical PKC isozymes (aPKC) that are insensitive to phorbol esters but are activated by phosphatidylserine and include PKC ζ and λ . A recently described protein kinase C μ (human) and its murine homolog PKD, form a distinct class in that it is activated by phorbol esters and is phospholipid-dependent, but calcium insensitive. It has a kinase core similar to that of calmodulin-dependent kinases and no pseudosubstrate motif has been identified. However, it contains two unique hydrophobic domains in the N-terminal portion (putative transmembrane sequences) of the enzyme, a pleckstrin homology domain and a distinct catalytic domain structure. Another class of PKC, the PKC-related kinases (PRK) consists of three members: PRKs 1, -2 and -3. PRKs are insensitive to Ca^{2+} , DAG and phorbol esters (Palmer *et al.*, 1995c, pp.315-320; Mukai *et al.*, 1994b, pp.897-904). PRK family binds to RhoA, which leads to its activation (Vincent *et al.*, 1997, pp.2247-2256; Amano *et al.*, 1996, pp.648-650; Quilliam *et al.*, 1996, pp.28772-28776; Watanabe *et al.*, 1996, pp.645-648).

Table 1. PKC Isozyme Family

(Nishizuka, 1986, pp.305-312; Newton, 1997, pp.161-167).

CLASS	MOLECULAR WEIGHT	ACTIVATORS
Conventional PKCs (cPKC)		
α	76.8 kDa	PS, DAG, Ca^{+2} , phorbol esters
βI	76.8 kDa	PS, DAG, Ca^{+2} , phorbol esters
βII	76.9 kDa	PS, DAG, Ca^{+2} , phorbol esters
γ	78.4 kDa	PS, DAG, Ca^{+2} , phorbol esters
Novel PKCs (NpkC)		
δ	77.5 kDa	PS, DAG, phorbol esters
ϵ	83.5 kDa	PS, DAG, phorbol esters
η	78.0 kDa	PS, DAG, phorbol esters
θ	81.6 kDa	PS, DAG, phorbol esters
Atypical PKCs (aPKC)		
ζ	67.7 kDa	PS
λ/ι	67.2 kDa	PS
Protein kinase C μ / PKD	?	PS, phorbol esters

PS, phosphatidyl serine; DAG, diacylglycerol; Ca^{+2} , calcium

Structure of protein kinase C

Cloning of the cDNA and extensive biochemical and mutational analysis has indicated that the primary amino acid structure of the PKC isozymes is composed of conserved domains (C1-C4), that serve as functional modules, and are separated by variable domains (V1-V5) that contribute to isozyme specificity and function.




Figure 1. Schematic representation of the PKC isozymes domain structure.

V1 to V5 are the variable regions while C1 to C4 are the common (or conserved) regions. The regulatory domain comprises of the pseudosubstrate site, and one or two of the membrane-targeting motifs, namely C1 present in all PKCs and C2 present in cPKCs and nPKCs. The regulatory domain is separated from the catalytic domain by the hinge (or V3) region. The catalytic domain consists of the ATP-binding and substrate binding sites, the C3 and C4 regions respectively.

The N-terminal regulatory domain and the C-terminal catalytic domain structure of PKC isozymes are diagrammed in Figure 1. The N-terminal V1 domain of cPKC isozymes is approximately 20 amino acids while that of the nPKC isozymes is longer and may contribute to regulate the functions of the conserved domains. The autoinhibitory domain contains a pseudosubstrate site (at amino acids 22 to 28) that cannot be phosphorylated and blocks the catalytic site. The C1 domain, that immediately follows

the pseudosubstrate sequence, binds to diacylglycerol and phorbol esters. It is present as a tandem repeat of two domains in most PKCs except within the atypical PKC isozymes that have only one copy of this domain. The C1 domain contains a cysteine-rich region that comprises of two zinc-finger motifs each with six Cys-residues, that co-ordinates two Zn^{2+} ions, and a DNA-binding motif. No obvious role has yet been elucidated for the Zn^{2+} ions. The C2 domain contains a binding site for acidic lipids and represents the Ca^{2+} binding domain of the Ca^{2+} dependent PKC isozymes (the novel PKC isozymes notably lack this Ca^{2+} binding domain). The V3 or hinge region separates the regulatory and catalytic domains and becomes proteolytically labile when the enzyme translocates to the membrane on activation. On proteolysis, the pseudosubstrate inhibition is relieved which leads to the generation of the constitutively active kinase domain (protein kinase M). The C3 domain contains an ATP-binding motif, xGxGx₂Gx₁₆Kx, which is conserved in all protein kinases. The C4 domain contains the substrate-binding site and the phosphate transfer region containing the conserved sequence DFG (Kemp *et al.*, 1990, pp.342-346). The V5 region confers specific function and role to the alternatively spliced PKC β forms i.e. PKC - β I and - β II. The V5 region is involved in substrate specificity and protein trafficking. Protein kinase C μ or PKD has a unique structure in that it contains two hydrophobic domains in the N-terminal (putative transmembrane sequences), a putative pleckstrin homology domain and a distinct catalytic domain.

Tissue, cellular and subcellular localization of PKCs

PKC isozymes show distinct tissue, cellular and subcellular distribution and more than one isoform could be expressed in a cell type (Table 2). PKC α , β I, β II, γ , δ , ϵ and ζ are expressed in the brain. PKC γ is exclusively expressed in the brain and spinal cord. PKC η , θ and λ are abundant in skin and lung, skeletal muscle, and ovary and testis. This preferential expression could imply tissue specific functions while the ubiquitous expression could suggest that the PKCs are essential for general cell function.

Several PKCs are differentially expressed in various regions and cell types of the brain. PKC γ predominates in the dendrites, cell bodies and axons of Purkinje, PKC α , β I, β II and γ are contained in the neurons of the brain. Glial cells also selectively express PKC α and β II.

Table 2. Tissue Expression of PKCs

PKC ISOFORMS	TISSUES EXPRESSING HIGHEST LEVELS
Conventional PKCs (cPKC)	
α	Ubiquitous
β I (or β 2)	Brain, heart, spleen, vascular smooth muscle
β II (or β 1)	Brain, heart, spleen, vascular smooth muscle
γ	Brain, spinal cord
Novel PKCs (nPKC)	
δ	Brain, myeloid cells
ϵ	Brain
η	Skin, lung, skeletal muscle, ovary, testis
θ	Skin, skeletal muscle
Atypical PKCs (aPKC)	
ζ	Brain
λ /i	Skin, skeletal muscle

PKC isozymes have been shown to translocate to the nucleus upon activation. Phorbol esters translocate PKC α to 3T3 fibroblast nuclei while PKC β in HL60 cells is translocated to the nuclei by phorbol ester activation. PKC β has also been found in liver nuclei. The presence of PKC isozymes in the nucleus suggests that activation of PKC in the nucleus may be important for regulation of gene expression.

The PKC β gene

The molecular cloning and biochemical experiments on the genomic structure of the PKC isozymes reveals that they are encoded on distinct chromosomes except PKC β I and - β II which are alternatively spliced products derived from a single PKC β gene. The

variable V5 domain of the PKC β gene is alternatively spliced to generate PKC β I or PKC β II mRNAs. The β I and β II cDNAs, from rat or rabbit brains, encode 671 and 673 amino acid sequences respectively. The resulting proteins differ in their carboxyl terminal regions by 50-52 amino acid residues.

Alternative splicing of the PKC β pre-mRNA, shown in Figure 3, generates the mature PKC β I mRNA and the exon-included PKC β II mRNA that shares a common 3' untranslated region and poly (A) tail with PKC β I mRNA. This insertion into the coding region introduces a termination codon near the splice site such that the PKC β II sequence is only two amino acids longer than PKC β I polypeptide. As shown in Figure 4, the PKC β II cDNA is longer than the PKC β I cDNA by means of insertion of a 216 bp independent exon.

PKC β II cDNA is longer than the PKC β I cDNA by means of insertion of a 216 bp independent exon.




Figure 2. A schematic representation of PKC β sequence as deduced from the cDNA analysis.

The V5 region of alternative splicing for PKC β I and PKC β II is indicated. The resulting amino acids for PKC β I and PKC β II consist of 671 amino acids and 673 amino acids respectively.




Figure 3. Alternative splicing of PKC β pre-mRNA.

- (a) Introns are represented by lines while the boxes represent exons. The approximate sizes of the introns and exons of the 3' end of PKC β gene are indicated.
- (b) The polyadenylation site contains the hexanucleotide AUUAAA. Splicing of the last common exon C4 to β IV5 exon produces the mature PKC β I mRNA whereas the PKC β II mRNA has the β IIIV5 exon included. Both PKC β I mRNA and PKC β II mRNA have a common 3' untranslated region and poly(A) tail.




Figure 4. PKC β II mRNA is generated via exon inclusion in the alternative splicing of PKC β .

The 5' end of PKC β cDNA contains 684 nucleotides of untranslated sequence followed by ATG (initiation site) at 685 bp position in the C4 region. PKC β I mRNA is generated by splicing of the β I exon at position 2547. The PKC β II mRNA is generated via inclusion of a 216 bp exon at position 2547. This alternative splicing introduces a STOP codon (TAA) at position 2763 in PKC β II mRNA. The coding regions of PKC β I and PKC β II cDNA are followed by 504 nucleotides and 714 nucleotides, respectively in the 3'-untranslated region. The resulting proteins differ in their carboxyl terminal regions by 50-52 amino acid residues (Ono et al, 1987, pp 1116-1120).

The expression of the PKC β gene is developmentally regulated and shows cell type specificity (Niino, S. *et al.*, 1992, pp.6158-6163). To determine the mechanism for the cell type specificity of transcription of PKC β gene, Niino et al (Niino, Y., S., S. Ohno,

and K. Suzuki. 1992. Positive and negative regulation of the transcription of the human protein kinase C β gene. J. Biol. Chem. 267:6158-6163.) demonstrated the presence of multiple *trans*-acting factors that act on positive and negative *cis*-acting elements and regulate transcription of the human PKC β gene, hence providing an explanation for regulation of its cell-type specific expression. Obeid et al (Obeid, L. M., G. C. Blobe, L. A. Karolak, and Y. A. Hannun. 1992. Cloning and characterization of the major promoter of the human protein kinase C β gene. Regulation by phorbol esters. J. Biol. Chem. 267:20804-20810) have cloned the 5' region of the gene for PKC β and identified its promoter. Although the mRNAs for PKC β I and PKC β II are distinct, the transcription of both the mRNAs is under the regulation of the common PKC β promoter. The transcriptional initiation site is 197bp upstream of the translational initiation site. The promoter region for PKC β is GC-rich (>80%) and the TATA and CAAT elements are found upstream of the transcription start site in the reverse order. Other regulatory *cis*-acting elements are shown in Table 3.

Table 3. Potential trans-acting factors regulating cis-acting elements in the promoter region of the PKC β gene.

<i>TRANS</i> -ACTING FACTOR	<i>CIS</i> -ACTING ELEMENT	POSITION IN PKC β GENE
Oct BP	ATGCAAAT	-76
Sp1	GGGCGG	-94, -63
E _{12/47}	GCAGGTGG	-110, -26, +18
ChoRE	CACGTG	-318 (CACCCG), -226 (CTCCTG)
AP ₂	CCCCACCCC	-330

CTF/NF-1	GCCAAT	-395
AP ₁	TGAGTCA	-442
TFIID	TATAAA	-530

To study the promoter elements, Obeid, et al (Obeid, L. M., G. C. Blobe, L. A. Karolak, and Y. A. Hannun. 1992). Cloning and characterization of the major promoter of the human protein kinase C β gene. Regulation by phorbol esters. J. Biol. Chem. 267:20804-20810) used deletion constructs of PKC β gene. A 154-bp construct (-111 to +43) that contained an octamer motif, two Sp1 sites and one E box could confer promoter activity. This indicated that the TATA or CAAT motifs were not required for basal promoter activity. They further demonstrated that the phorbol esters transcriptionally up-regulated PKC β in K562 erythroleukemia cells. A feedback loop exists which acts to induce *de novo* transcription of PKC β when phorbol esters activate PKC β and cause its down-regulation.

Activation of protein kinase C

Signaling pathways that generate PKC activators

Stimulation of cell surface receptors activates phospholipase C which hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP₂) resulting in the production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP₃). Inositol 1,4,5-trisphosphate stimulates the release of Ca²⁺ from intracellular storage (see Figure 5). Furthermore, DAG is also produced from phosphocholine and results in a sustained elevation of DAG in response to various signals like phorbol esters, growth factors and cytokines. Both DAG and Ca²⁺

mediate the activation of PKC isozymes as shown in Figure 6. Ca^{2+} binds to C2 domain of cPKC isozymes. Translocation of the enzyme to the membrane enables its activation by DAG and phosphatidylserine, which is a membrane acidic lipid, through binding at its C1 domain.




Figure 5. Generation of PKC activators.

Ligand binding to the receptor activates phospholipase C (PLC) which generates diacylglycerol (DAG) and Ca^{2+} . $\text{PtdIns}(4,5)\text{P}_2$: phosphatidylinositol 4,5-bisphosphate; $\text{PtdIns}(1,4,5)\text{P}_3$: phosphatidylinositol 1,4,5-trisphosphate.




Figure 6. Activation of PKC by diacylglycerol and Ca²⁺.

Ligand binding to the receptor activates phospholipase C (PLC) which hydrolyses phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P₂) to diacylglycerol (DAG) and Ca²⁺. Phospholipase A₂ (PLA₂) is also activated which hydrolyses phosphocholine (PC) to lysophosphatidylcholine (Lyso PC) and free fatty acids (FFA). This results in increased levels of DAG thereby prolonging PKC activation for sustained cellular responses.

Model for regulation and activation of protein kinase C

For protein kinase C to be functionally active, the newly synthesized enzyme is first localized on the cytoskeleton and rendered catalytically competent by phosphorylations. Mass spectroscopy has revealed that PKC is phosphorylated at three positions *in vivo*. The residues corresponding to these phosphorylations in PKC β II include Thr500 in the activation loop, Thr641 and Ser660 at the carboxyl terminus. This triple phosphorylated mature form is inactive because the pseudosubstrate occupies the substrate-binding site. As diagrammed in the Figure 7, the next step requires the removal of the autoinhibitory pseudosubstrate domain from the kinase core. Activation of protein kinase C by diacylglycerol, Ca²⁺ or phosphatidylserine, and subsequent translocation to the membrane, renders the pseudosubstrate sensitive to proteolysis by trypsin or endoproteinase Arg-C. Maximum binding affinity of PKC to the membrane, mediated by domains C1 and C2, releases the pseudosubstrate inhibition. The exposed V3 domain hinge also, becomes proteolytically labile on membrane binding (independent of pseudosubstrate release).

Localization of PKC isozymes by anchoring proteins

Both active and inactive PKC isozymes are localized to specific intracellular sites due to their binding to specific anchoring molecules. The anchoring proteins for activated PKC isozymes are termed receptors for activated C-kinase (RACKs) while proteins




Figure 7. Model for activation of PKC.

Newly synthesized PKC is bound to the cytoskeletal. Upon phosphorylation, it translocates towards the membrane but is still inactive due to the pseudosubstrate binding. Diacylglycerol, Ca^{2+} and phosphatidylserine activate PKC which binds to the membrane via its C1 and C2 domains and is released from the pseudosubstrate inhibition.




Figure 8. Localization of PKC isozymes by anchoring proteins.

Both active and inactive PKC isozymes are localized to their specific intracellular sites due to their binding to the specific anchoring molecules. Receptors for inactive C-kinase (RICKs) bind to the inactive PKC isozymes in the cell cytoskeleton in a phosphatidylserine-dependent manner. Receptors for active C-kinase (RACKs) bind to the activated PKC isozymes in a selective and saturable manner at a site distinct from the substrate-binding site.

that anchor inactive PKC isozymes are termed receptors for inactive C-kinase (RICKs). RACKs are present in the cell particulate fraction and bind to activated PKC isozymes in a selective and saturable manner. For example, RACK1 - a PKC β II-specific RACK, co-localizes with activated PKC β II to the perinucleus in cardiac myocytes (Ron *et al.*, 1994,

pp.839-843) and enhances its activity. PKC ϵ binds to F-actin *in vitro* and in synaptosomes through ϵ RACK and thus F-actin may show characteristics of ϵ RACK (Prekeris *et al.*, 1996, pp.77-90). Blobe *et al* (Blobe *et al.*, 1996, pp.15823-15830) have shown that PKC β II, and not PKC β I, binds to F-actin and stimulates PKC β II activity. These observations may suggest that F-actin may have the characteristics of both ϵ RACK (Prekeris *et al.*, 1996, pp.77-90) and β IIRACK (Ron *et al.*, 1994, pp.839-843).

In inactive PKC, a binding site for RICK is exposed. On activation, PKC isozymes bind to RACKs, altering its conformation and exposing the substrate-binding site. As depicted in Figure 8, RICK binding site is eliminated. Binding of anchoring proteins to PKC isozymes is mediated through phosphatidylserine (PS) or lipid bridges and through direct protein-protein interactions. These anchoring proteins could contribute to another level of regulation of PKC signaling and provide a platform for cross-talk between PKC isozymes.

Carbohydrate Response Element (ChoRE)

Glucose, the preferred energy source for most eukaryotic cells, alters gene expression in diverse cell types. Glucose stimulates insulin gene expression in pancreatic β -cells, IGF-1 expression in glioma cells, liver-type pyruvate kinase (L-PK) and S_{14} gene expression in hepatocytes and alters epidermal growth factor signaling in rat fibroblasts. Towle *et al* first described the carbohydrate response element (ChoRE) in the S_{14} gene that is regulated by glucose (Sayeski, P. P. and J. E. Kudlow. 1996. Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor- α gene expression. *J. Biol. Chem.* 271:15237-15243) in hepatocytes. A consensus motif

comprising of 5' CACGTG 3' is central for the glucose response in both the L-PK and S₁₄ genes. CACGTG motif is also the core-binding site for the c-Myc family of transcription factors. Two copies of CACGTG motif (with a 4 bp out of 6 bp match) separated by a 5bp spacer is critical for glucose control of gene expression. The requirement for two CACGTG motifs suggests that two identical or closely related factors may bind to provide the carbohydrate response noted for transcription of the L-PK and S₁₄ genes.

Although a carbohydrate response factor has not yet been described, we could speculate the mode of action of such a factor. Glucose or its metabolite could serve as a direct activator by binding to the ChoRE. An example is the peroxisome proliferating-activated receptor (PPAR), a member of the thyroid/retinoic acid nuclear receptor family. PPAR activates genes involved in fatty acid oxidation by binding directly to DNA response elements of these genes (Nakshatri *et al.*, 1998, pp.2491-2499). Alternatively, a covalent modification such as phosphorylation/dephosphorylation, in response to carbohydrate metabolism might modify the carbohydrate response factor.

The pathogenesis of atherosclerosis

Vascular smooth muscle cell proliferation is a principal contributor to the development of atherosclerosis and hypertension - the two major forms of vascular disease. Atherosclerosis is the predominant factor in the advent of heart attack, stroke and gangrene of the extremities. It is responsible for approximately 50% of all mortality in the USA, Europe and Japan. Blood vessels begin as endothelial channels and develop into adult arteries by differentiation of smooth muscle cells.

Replication of smooth muscle cells occurs as the initial event in the formation of atherosclerotic lesions, preceding lipid accumulation or endothelial injury. Smooth muscle cells may be stimulated to proliferate and develop atherosclerotic plaques within the intimal thickenings (Orekhov *et al.*, 1984, pp.17-24; Santen *et al.*, 1972, pp.833-843). Plaques consist of focal proliferation of smooth muscle cells and accumulation of foam cells and extracellular lipid within the thickenings (Schwartz *et al.*, 1986, pp.427-444). In the early stages of the atherosclerotic process, smooth muscle cells migrate from the media to the intima of the arterial wall. Here, the smooth muscle cells proliferate and deposit extracellular matrix components forming a lesion.

The advanced lesions of atherosclerosis become a disease when in excess and can occlude the artery. The endothelium and smooth muscle cell walls respond to various forms of injury or trauma with excessive inflammation and proliferation.




Figure 9. Arterial smooth muscle cell phenotypes.

In the contractile phenotype the smooth muscle cells show a heterochromatic nucleus and abundant actin and myosin filaments. In the process of atherogenesis, the smooth muscle cell structure modifies to a synthetic phenotype that has a euchromatic nucleus, prominent ER and golgi complex and a decrease in the content of myofilaments. Cells in the synthetic phenotype produce extracellular matrix components that aid in proliferation.

The major hypothesis explaining smooth muscle cell replication and proliferation in the blood vessel is the “response to injury” hypothesis presented by Ross in 1986 (Ross, R. 1986. The pathogenesis of atherosclerosis--an update. New England Journal of Medicine 314:488-500). Ross proposed that smooth muscle cells in the wall normally exist in a quiescent state. The principal source of connective tissue in the arterial wall is the smooth muscle cell. Smooth muscle cells show two different phenotypes, synthetic or contractile,

based on the presence and distribution of myosin filaments and secretory protein apparatus, endoplasmic reticulum and Golgi. As diagrammed in Figure 9, the primary role of the smooth muscle cell in the synthetic phenotype is proliferation whereas in the contractile phenotype, it contracts in response to external stimuli.

Injury to the endothelium can be caused by exposure to agents like oxidized LDL, toxins, and viruses or may result from mechanical stress. In response to the injury, the endothelium releases potent growth-regulatory molecules that stimulate smooth muscle cell movement and proliferation into the arterial wall. Growth factors, cytokines, lipids and molecules like nitric oxide induce cell recruitment and migration, cell proliferation and control lipid and protein synthesis in the process of atherogenesis.

As the process continues, monocytes become macrophages on reaching the arterial surface, and accumulate lipid. It then proceeds to become foam cells and together with accompanying lymphocytes become the fatty streak predominantly at branch points of the artery. Continued cell influx and proliferation of the smooth muscle cells lead to advanced lesions and ultimately to the fibrous plaque. Figure 10 shows a representation of the Ross model. Likewise, there is a shift from the contractile to the synthetic phenotype. Progression of atherosclerotic lesions is accelerated by increased smooth muscle cell proliferation.





Figure 10. Representation of the response-to-injury hypothesis of atherosclerosis proposed by Ross.

Exposure to agents like oxidized LDL, toxins and viruses causes an injury to the endothelium and results in the release of growth factors, cytokines and nitric oxide. The smooth muscle cells migrate from the media to the arterial intima where they proliferate and deposit extracellular matrix components thereby forming a lesion.

Diabetes Mellitus

The prevalence of atherosclerotic vascular disease among diabetic patients occurs more frequently as compared to normal subjects. Diabetes mellitus is one of the major causes of mortality and disability in all ages. Diabetes mellitus is an endocrine disorder caused by relative or total deficiency of insulin action. Hyperglycemia, abnormally high blood glucose level, is the diagnostic hallmark of diabetes. Insulin-dependent or type I diabetes has early onset and is caused by the destruction of pancreatic β cells such that insulin is no longer produced. Non-insulin dependent or type II diabetes occurs in middle to older aged individuals. Patients have reduced basal or glucose-induced insulin release or show insulin resistance. In either case, insufficient insulin action leads to overproduction and underutilization of glucose. The flux of glucose and its metabolites has diverse effects on many cellular processes. Various complications arise with hyperglycemia involving the cardiovascular tissue, peripheral nerves, retina, glomeruli and cells involved in wound healing. Excess glucose can alter signal transduction pathways via activation of diacylglycerol and protein kinase C isozymes.

Table 4. Diabetes Mellitus

	CAUSE	ONSET
Type I	Destruction of pancreatic β cells	Early
Type II	Insulin resistance	Late

Hyperglycemia and PKC signal transduction pathway

Hyperglycemia is responsible for increasing the risk of developing vascular complications by stimulating abnormal proliferation of vascular smooth muscle cells (VSMC). VSMC exhibit increases in proliferation in response to elevated glucose. Protein kinase C has been implicated as a mediator of diabetes-induced vascular proliferation. Hyperglycemia-induced increases in diacylglycerol (DAG) in tissues like aorta and heart and retina from diabetic rats leads to a sustained elevation of PKC. Multiple cellular and functional abnormalities in the diabetic vascular tissues have been attributed to the activation of DAG-PKC pathway. These include angiogenesis, cardiomyopathy, increased contractility in macrovessels, increased vascular permeability and neovascularization and other diabetic and neurological complications.

Glucose is incorporated into the glycerol backbone of DAG as shown by studies using labeled [^{14}C]- or [^3H]-glucose in aortic smooth muscle cells and aortic endothelial cells. The *de novo* synthesis pathway of DAG involves the metabolism of glycolytic intermediates. The fatty acids predominantly incorporated into DAG are palmitate and oleic acid along with glycerol-3-phosphate. The elevation of DAG in the vasculature induced by hyperglycemia or diabetes is maintained chronically. Thus, diabetic hyperglycemia leads to increased activation of PKC. Although, the PKC isozymes β and δ are predominantly detected by immunoblotting studies of vascular cells associated with the DAG-PKC pathway, PKC β II levels are preferentially elevated as a result of increased DAG levels in the aorta and heart of diabetic rats. In prior investigations, experiments were carried out using *in vivo* diabetic rat models subjected to chronic

glucose exposure for 2 to 4 months, see for example, Shiba et al (Shiba, T., W. Heath, R. Sportsman, and G. L. King. 1990. Characterization of the activation of protein kinase C isozymes in the retina of diabetic rats. Diabetes 39(Supplement 1):31A). PKC activity was examined in non-synchronized VSMC cultured under chronic high glucose conditions for 5 to 10 days. The increase in PKC activation was measured as increased translocation of the cytosolic PKC to the membrane.

Acute hyperglycemic conditions are prevalent even in controlled diabetic patients. It was established that hyperglycemia is linked to PKC β expression in vascular smooth muscle cells but the molecular mechanism was not elucidated. Studies of acute glucose exposure (from 0 to 24 hours) on PKC β gene expression in VSMC was not carried out. Further, the potential level(s) at which glucose could exert its effect on PKC β isozymes gene expression had yet to be determined. In order to extend our knowledge towards the immediate effects of hyperglycemia on vascular cell proliferation and function via the PKC pathway, a mechanistic study was undertaken.

Signal transduction

In order to coordinate growth, differentiation and response to the environment, cells of multi-cellular organisms have an intricate signaling network comprising of soluble signal molecules or direct contacts. Generally, a signaling molecule interacts with a cell surface receptor and initiates a cascade through the cytoplasm leading to the nucleus where the specific genes are regulated. Cell surface receptors such as receptor tyrosine kinase (RTK) or transforming growth factor- β receptors autophosphorylate and phosphorylate the cytoplasmic proteins in response to binding of an external ligand. A

complex series of intracellular responses results in diverse cellular responses as proliferation, differentiation, cell motility, production of extracellular matrix and transcription of specific genes.

Cytoplasmic signal transduction components include Ras, MAP kinase, PKC and other signaling pathways (Figure 11). Ras is a small membrane-bound guanine nucleotide-binding protein that acts as a molecular switch linking receptor tyrosine kinase activation to downstream signaling events. Ras cycles between an active GTP-bound form and an inactive GDP-bound form. The activity of Ras is regulated by Sos, a guanidine nucleotide exchange factor (GNEF). The carboxyl-terminal of Sos contains proline-rich motifs that mediate the interaction of Sos with Grb2, an adaptor molecule comprising of a SH2 domain flanked by two SH3 domains. Following receptor tyrosine kinase activation and autophosphorylation, Sos-Grb2 translocates to the plasma membrane and the vicinity of Ras, thereby activating Ras. The downstream effector of RasGTP is Raf, a serine/threonine kinase that links Ras to the MAP kinase pathway.




Figure 11. The MAP kinase pathway transduces the signal from the membrane to the nucleus.

Receptor tyrosine kinase (RTK) phosphorylation upon ligand binding activates Sos-Grb2 which further activates Ras. PKC is also an activator of Ras. The downstream target of Ras is Raf which can activate Mek. Mek phosphorylates MAP kinase which together with its target, ribosomal S6 kinase (Rsk) can translocate to the nucleus and activate transcriptional factors (TF) to regulate gene expression.

Mitogen-activated protein kinase (MAPK) or extracellular signal-regulated kinase (ERK) is a serine/threonine kinase that phosphorylates microtubule-associated protein (MAP). MAPK is phosphorylated in response to a variety of mitogens including nerve

growth factor (NGF), insulin, insulin-like growth factor II, and phorbol esters. MAP kinase kinase (Mek) activates MAP kinase by phosphorylating both tyrosine and threonine residues. Raf forms a stable complex with Mek and phosphorylates Mek on serine residues *in vitro*. Ribosomal S6 kinase (Rsk) is a component of the eukaryotic 40S ribosomal subunit that is phosphorylated on multiple serine residues in response to mitogen stimulation. Purified MAP kinase from insulin-stimulated cells could activate Rsk and comprise a step in the kinase pathway to transduce mitogenic signals to the nucleus. Thus the MAP kinase pathway (Figure 11), consisting of Ras, Raf, Mek, MAPK and Rsk spans from the plasma membrane to the nucleus and serves to transduce mitogenic signals downstream from the membrane receptor tyrosine kinases. Several components of this pathway such as Ras and Raf are oncogenic in their constitutively active form. MAP kinases can translocate to the nucleus upon mitogenic stimulation and regulate growth-specific gene expression. Transcriptional factors c-Myc and C/EBP β can be phosphorylated by MAP kinases *in vitro* and hence a spectrum of genes can be regulated by the MAP kinase pathway.

Nuclear responses to external signals can be achieved via the transcription factors or by nuclear receptors such as steroid receptors. In response to cytokines such as interferon α/β , the Jak/STAT pathway is activated to regulate the transcription of genes. The initial step is ligand-dependent dimerization of the receptors that brings the Janus kinases (Jaks) into close proximity. Jaks are constitutively associated with the receptor chain and are tyrosine phosphorylated upon receptor aggregation. The activation of Jak correlates with the tyrosine phosphorylation of the receptor components that recruit the

signal transducers and activators of transcription (STATs) through their SH2 domains which, in turn, are phosphorylated at their carboxy-terminal tyrosine residue. Homo- or heterodimers of the STATs translocate to the nucleus where they interact with the promoter elements or combine with DNA binding motifs.

Phosphoinositide-3-kinase (PI3-kinase) is implicated as a mediator of biological responses such as DNA synthesis, glucose transport, cytoskeletal rearrangements, cell survival, oocyte maturation and receptor internalization. PI3-kinase phosphorylates the inositol ring of phosphatidylinositol (PtdIns) to generate phosphatidylinositol-3-phosphate, PtdIns(3)P and further phosphatidylinositol-3,4-bisphosphate, PtdIns(3,4)P₂ and phosphatidylinositol-3,4,5-trisphosphate, Ptd(3,4,5)P₃. Further, phosphatidylinositol-3,4-bisphosphate is a substrate for phospholipase C which generates the second messengers Ptd(3,4,5)P₃ and diacylglycerol.




Figure 12. The role of phosphoinositide 3-kinase (PI3 kinase) in signal transduction.

Growth factor receptors with intrinsic tyrosine kinase activity recruit and activate PI3 kinase. The upstream activators and downstream targets of PI3 kinase are shown.

PI3-kinase consists of two subunits, p85 α and p110 α . The catalytic activity resides in the 110 kDa subunit while the 85 kDa subunit performs a regulatory role. As diagrammed in Figure 12, PI3-kinase is activated by several molecules that include cytoplasmic Src-family kinases, receptors with intrinsic tyrosine kinase activity, focal adhesion kinase (FAK), Ras-GTP, Rho and others. The downstream targets of PI3-kinase

include the protein kinase C family, p70-S6 kinase, glucose transporter GLUT4 (Hara *et al.*, 1994, pp.7415-7419), serine/threonine kinase Akt/Rac.

Protein Phosphatases

Reversible protein phosphorylation is a critical component of the signal transduction mechanisms in eukaryotes. It is the basis for the control of many biological events triggered by extracellular effectors like hormones, mitogens, oncogenes, cytokines and neurotransmitters. Reversible protein phosphorylation catalyzed by the opposing and dynamic action of protein kinases and phosphatases, is a ubiquitous element of intracellular signal transduction pathways that regulate metabolism, gene expression, cell division, differentiation, development, contraction, transport, cell locomotion, and learning and memory. Abnormal changes in the activities of the protein kinases and phosphatases can lead to severe consequences including immunological defects and cancer.

Protein phosphatases can be classified into three groups according to their substrate specificity.

1. **Serine/threonine phosphatases** dephosphorylate serine (Ser) and threonine (Thr) residues in proteins and usually require a divalent metal ion to function. They are further divided into two classes: type-1 phosphatase (PP1) preferentially dephosphorylates the β -subunit of phosphorylase kinase whereas the type-2 phosphatases (PP2) preferentially dephosphorylate the α -subunit of phosphorylase kinase. PP2 can be further subdivided into spontaneously active (PP2A), Ca^{+2} - and calmodulin-dependent (PP2B) and Mg^{+2} -dependent (PP2C) classes. Okadaic acid, a

polyether fatty acid and a potent inhibitor of protein phosphatases is cell permeable and serves as a valuable tool to study the functions of protein phosphatases. It is a potent inhibitor of PP2A ($K_i = 0.2\text{nM}$) and PP1 ($K_i = 20\text{nM}$) and a less potent inhibitor of PP2B ($K_i = 10\mu\text{M}$).

2. **Tyrosine phosphatases** dephosphorylate tyrosine (Tyr) residues in proteins and share a conserved active-site sequence motif Cys-X₅-Arg (X = any amino acid residue) and a Asp located in a surface loop. Protein tyrosine phosphatases (PTPs) are characterized by a signature sequence motif of 11 amino acid residues, (Ile/Val)-His-Cys-X-Ala-Gly-X-Gly-Arg-(Ser/Thr)-Gly that is found in most PTPs. The diversity within the PTPs arises from the variable N- or C-terminal sequences attached to the core catalytic domain.
3. **Dual-specificity phosphatases** dephosphorylate Ser/Thr residues in addition to Tyr residues in proteins. Their signature motif, His-Cys-X-X-Gly-X-X-Arg-(Ser/Thr) is analogous to PTPs but these phosphatases display a restricted substrate specificity.

Cell cycle and role of PKC β isozymes in the A10 vascular smooth muscle cells.

The process of cellular proliferation in eukaryotes includes the division of a cell into two daughter cells. Cell division involves mitosis in which the nuclear membrane dissolves, the chromosomes condense and separate into two groups, and two nuclear membranes reassemble around the chromosomes. Finally, in the process of cytokinesis, the cell membrane contracts in the middle and two halves separate to form individual cells.

The phases of the cell cycle that occur prior to cell division start with the G1 phase. The S phase follows in which the chromosomes are replicated and the cell then enters the G2 phase where the preparation for mitosis (M phase) occurs. Cell cycle regulation predominantly occurs during the G1/S transition and the G2/M transition.

Vascular smooth muscle cells (VSMC) cultured in plasma-derived medium are unable to proliferate and are arrested in the G0 phase. These quiescent cells progress into the S phase upon addition of growth factors and begin DNA synthesis (Ross *et al.*, 1978, pp.497-508). It has been demonstrated that PKC β I stimulated while PKC β II inhibited the G1/S transition. VSMC proliferation is accelerated when the inhibitory role of PKC β II on proliferation is disrupted. Further, the overexpression of PKC β I shortened the S phase while the overexpression of PKC β II prolonged the S phase suggesting a role for PKC β I and - β II in the entry of G2/M phase. The requirement for PKC β II for the G2/M phase transition of cell cycle has also been shown in HL60 cells.

Levels of gene regulation

All cells regulate gene expression in response to changes in the external environment. Nutritional and metabolic signals play an important role in controlling gene expression.

Levels of regulation in eukaryotes is shown in Figure 13. The central dogma of biochemistry states that the genes are aligned on the chromosomes and are made of DNA which is transcribed into RNA, followed by translation into proteins. RNA also undergoes maturation by post-transcriptional modifications like the 5' methylation and capping, 3' polyadenylation, alternative or differential splicing according to tissue

specificity and editing. The processing in eukaryotic mRNA occurs in both the nucleus and cytosol and involves a fine balance between transcriptional and posttranscriptional levels. The protein undergoes post-translational modifications such as glycosylation, farsenylation and addition of signal peptides for maturation.

Post-transcriptional regulation of the mRNA stability establishes the steady state level of the transcript. Although the steady state level of any mRNA depends on both the rate of synthesis and degradation of the mRNA, abundance of many mRNAs is correlated with the longevity of the transcript.

The RNA transcript is initially synthesized as the heterogeneous nuclear RNA by the action of RNA polymerase II on genomic DNA, and is further processed into mature mRNA within the nucleus. It is then translocated into the cytoplasm where its fate is determined. The mature mRNA can undergo localization, degradation or be translated into the protein (see Figure 14).




Figure 13. Levels of eukaryotic gene regulation.

DNA is transcribed to RNA which upon post-transcriptional modification is translated to proteins. The pool of nucleotides and amino acid is refurbished by mRNA and protein degradation, respectively.

Messenger RNA degradation in eukaryotic cells is a regulated process that represents a powerful means for controlling gene expression. mRNA decay is not a random process involving degradation by nucleases. Rather, it is a precise process orchestrated by *cis* elements coordinating with the *trans-acting* factors in controlling gene expression.





Figure 14. The fate of mRNA in mammalian cells.

RNA polymerase II synthesizes the heteronuclear RNA (hnRNA) transcript from the genomic DNA that undergoes post-transcriptional modifications before the mature mRNA is translocated into the cytoplasm. According to the cellular signals, the mRNA is either translated to protein or it can undergo degradation. Localization of mRNA to free, cytoskeletal-bound or membrane-bound polysomes also takes place in the cytoplasm.

mRNA stability



- | | |
|--------------------------------|-------------------------|
| 1 5' cap | 5 3' UTR sequences |
| 2 5' UTR | 6 ARE sequences |
| 3 premature stop codons | 7 3' terminal stem loop |
| 4 open reading frame sequences | 8 poly(A) tail |

Figure 15. Representation of the structural elements involved in regulating mRNA stability.

The cis-elements to which trans-acting factors bind to modulate the half-life of the mRNA are depicted.

The elements involved in the regulation of transcript stability are shown in Figure 15. mRNAs can contain two or more separated stability determinants, each of which may be involved in a distinct decay pathway or a specific response to a regulatory factor. For instance, multiple elements within the interleukin-2 (IL-2) mRNA modulate its stability in a combinatorial manner. Although the 3'UTR with its AU-rich elements are primarily involved in regulating stability, the 5' UTR and its immediate coding region contain an element that confers c-jun NH₂-terminal kinase (JNK)-mediated stabilization.

1. **5' cap:** The mRNA cap is important in preventing the degradation of transcripts. mRNAs without caps are fourfold less stable than capped mRNAs as observed in oocytes and cell-free *in vitro* decay reactions. Decapping could be a rate-limiting step in mammalian mRNA decay. The mRNA cap may be involved in the translational activity of the transcript that could then modulate its rate of degradation.
2. **5' untranslated region (5' UTR):** The half-life of mRNAs is affected by its 5' UTR and its influence on translational regulation. The presence of a secondary structure, like a stem-loop, can inhibit translation. The ferritin mRNA contains an iron responsive element (IRE) in its 5' UTR that affects its translation. Ferritin is a major intracellular iron storage protein. Under low iron conditions, an iron responsive protein binds to the IRE and represses translation.

The 5'UTR of the long-lived *Escherichia coli* ompA transcript functions as an mRNA stabilizer that prolongs the cytoplasmic lifetime of mRNAs by hindering distinct mRNA pathways for mRNA degradation. Two domains of the 5'UTR are responsible in this stabilizing effect: the 5'-terminal stem loop and the single stranded RNA segment (ss2) that contains a ribosome binding site.

3. **Premature stop codons:** Nonsense codons lead to abrupt termination of translation. Another function attributed to some early premature stop codons is to decrease the levels of nuclear-associated transcripts, thereby reducing the steady state levels of mature mRNA available for translocation to the cytoplasm. This is also observed in phytohemagglutinin mRNA whose stability is decreased by the presence of premature nonsense codons.

4. **Coding region sequences:** Sequences within the coding region can also play a role in determining the mRNA half-life. Stability determinants have been demonstrated within the coding regions of *c-myc* mRNA and *c-fos* mRNA. *c-fos* is a rapidly inducible gene involved in immediate early response. It contains three stability determinants - one in the 3' UTR and two in the coding region. One of the coding-region determinants encodes the basic and leucine zipper regions and its structure specifies the instability of mRNA irrespective of the protein binding to it. Another example is that of *c-myc* mRNA coding region that influences the mRNA half-life via a C-terminal determinant containing a part of the helix-loop-helix and the entire leucine zipper motif (Ross, 1995, pp.423-450). The capsid protein L2 of the human papillomavirus (HPV) type 16 contains *cis*-acting inhibitory sequences in its coding region that act in an orientation dependent manner to reduce cytoplasmic and nuclear mRNA levels. In the case of *Synechococcus* sp. strain PCC 7972, the 5'UTR acts mutually with the coding-region stability determinant to regulate its stability.

Bernstein, P. L., D. J. Herrick, R. D. Prokipcak, and J. Ross. 1992. Control of *c-myc* mRNA half-life invitro by a protein capable of binding to a coding region stability determinant. *Genes Dev.* 6:642-654 demonstrated a protein binding within a *c-myc* coding region that affected its stability. Proteins that bind to mRNA coding region are implicated in determining the decay rate of the mRNA. Proteins binding to *c-fos* and *c-myc* coding region stability determinants have been described that influence the mRNA stability. A 70 kDa polysome-associated protein that binds to the *c-myc* coding region has been identified and purified (see, for example Prokipcak, R. D., D. J. Herrick, and J. Ross.

1994. Purification and properties of a protein that binds to the C-terminal coding region of human c-myc mRNA. J. Biol. Chem. 269:9261-9269) and serves to protect it from endonucleolytic attack. The urokinase-type plasminogen activator receptor (uPAR) mRNA stability is regulated by a 50-kDa protein binding to a 51-nucleotide fragment in the coding region.

In the case of the β -tubulin mRNA, destabilization is initiated by excess tubulin monomers encoded by the coding-region stability determinant. However, at present date, involvement of a protein in this autoregulation has not been demonstrated.

5. **3' untranslated region (3' UTR):** The majority of research has focused on the stability determinants that lie in 3' UTR of the mRNAs. The best-characterized stability determinants are in the 3'UTR of the mRNAs for transferrin receptor. The transferrin receptor imports iron into cells. Post-transcriptional regulation is achieved through a iron responsive element (IRE) which functions by binding an iron regulatory protein (IRP). When intracellular iron concentration is abundant, the IRE-IRP complex does not form and the transferrin receptor is unstable. When the concentrations of iron are low, the formation of the IRE-IRP complex stabilizes the transferrin receptor. Another example is that of ribonucleotide reductase R2 mRNA which contains a *cis*-element in the 3' UTR that is regulated by the TGF- β family. Treatment with TGF- β_1 , TGF- β_2 , or TGF- β_3 stabilizes the ribonucleotide reductase R2 mRNA. The GAP-43 mRNA (GAP-43 is a neuronal protein) in undifferentiated PC12 cells contains pyrimidine-rich sequences in its 3'UTR that bind to two proteins and regulate its stability.

6. **Adenosine-uridine (AU) rich sequences:** AU-rich elements (AUREs or AREs) are found in the 3' UTR of mRNAs that encode proto-oncogenes, nuclear transcription factors and cytokines and represent the most common RNA instability determinants characterized in mammalian cells. The AUREs generally contain one or more copies of the AUUUA pentanucleotide and a high content of uridylylate and sometimes adenylylate residues. A nonamer with an AUUUA core, UUAUUUA(U/A)(U/A), is suggested to be a better indicator in predicting the destabilizing function of the AU-rich sequences. AUREs facilitate rapid deadenylation as the first step in mRNA degradation. The destabilizing activity of an AURE can be increased or decreased by interactions in *cis* with other sequences like a U-rich region or interactions with *trans*-acting regulatory factors like the AU-binding proteins (AUBPs). The AREs can be distinguished into three classes: Class I AUUUA-containing AREs direct the synchronous shortening of poly A tails to 30 to 60 nucleotides before mRNA decay; Class II AUUUA-containing AREs direct the asynchronous shortening of poly A tails, with intermediate fully deadenylated products; and a novel class of non-AUUUA ARE described in the *c-jun* proto-oncogene mRNA which are insensitive to blockage of their effects by the addition of transcription inhibitors.
7. **3' terminal stem loop structure:** The histone gene transcripts are cell cycle regulated with large number of molecules present during the S phase and a dramatic decline at the end of the S phase. The histone mRNAs are not polyadenylated but the presence of a 3' terminal stem loop structure confers cell cycle regulation of transcript stability.

A stem-loop binding protein and histone proteins themselves might be involved in the regulation process.

8. **Poly(A) tail:** The polyadenylated tail has multiple functions affecting nuclear processing of pre-mRNA, transport to the cytoplasm, translation, and cytoplasmic mRNA stability. The poly(A) tail via binding to the poly(A) binding proteins (PABPs), protects mRNAs from rapid or indiscriminate degradation. Polyadenylation can affect transcript stability in mammalian cells by the poly(A) addition site selection used during processing of hnRNA into mature mRNA as seen in the case of insulin-like growth factor I.

Post-transcriptional regulation of gene expression is a critical step in determination of steady state levels of the mRNA. The stability of mRNA can also be influenced by a variety of exogenous factors such as hormones, ions or nutrients (Ross, 1995, pp.423-450). The processing of mRNA involves *cis* elements present in the transcript that are recognized by specific RNA-binding proteins and participate in RNA masking, mRNA stabilization, and/or movement of mRNAs among different ribosome populations within the cell.

Summary Of The Present Invention

Complications involved in cardiovascular tissue injury recovery are aggravated with episodes of acute hyperglycemia. Protein kinase C (PKC) has been implicated as a mediator of diabetes-induced vascular proliferation. Diabetic conditions, especially acute hyperglycemia, may provoke the excessive formation of atherosclerotic lesions that may ultimately lead to the formation of the fibrous plaques. This study elucidates molecular

events occurring after initiation of the cell cycle in quiescent vascular smooth muscle cells following exposure to acute hyperglycemic conditions.

PKC β II is the predominant isoform detected in quiescent smooth muscle cells although these cells also express PKC α , - β I, - δ and - ϵ . Our previous studies indicate that PKC β I and PKC β II regulate the vascular smooth muscle cell cycle. In A10 cells (a clonal cell line of VSMC) transfected to overexpress PKC β II, DNA synthesis was attenuated. This suggested that PKC β II might function as a cell cycle mediator during G1/S phase transition in VSMC. It was demonstrated that PKC β II protein expression was decreased and the percentage of A10 cells entering the S phase was increased in VSMC in the presence of acute high extra-cellular glucose concentrations. Northern blot studies indicated that the steady-state levels of PKC β mRNA were decreased by high glucose. Based on these findings, it was hypothesized that the hyperglycemia-induced proliferation of VSMC may be related to the regulation of PKC β gene expression by glucose.

Brief Description Of The Drawings

Figure 1. Schematic representation of the PKC isozymes domain structure

Figure 2. A schematic representation of PKC β sequence as deduced from the cDNA analysis

Figure 3. Alternative splicing of PKC β pre-mRNA

Figure 4. PKC β II mRNA is generated via exon inclusion in the alternative splicing of PKC β

Figure 5. Generation of PKC activators

Figure 6. Activation of PKC by diacylglycerol and Ca²⁺

Figure 7. Model for activation of PKC

Figure 8. Localization of PKC isozymes by anchoring proteins

Figure 9. Arterial smooth muscle cell phenotypes

Figure 10. Representation of the response-to-injury hypothesis of atherosclerosis proposed by Ross

Figure 11. The MAP kinase pathway transduces the signal from the membrane to the nucleus

Figure 12. The role of phosphoinositide 3-kinase (PI3 kinase) in signal transduction

Figure 13. Levels of eukaryotic gene regulation

Figure 14. The fate of mRNA in mammalian cells

Figure 15. Representation of the structural elements involved in regulating mRNA stability

Figure 16. PKC β I protein levels remain unaltered in the presence of high glucose

Figure 17. PKC β II protein levels decreased by 55% in the presence of glucose

Figure 18. Down regulation of PKC β (I+II) mRNA by glucose

Figure 19. Map of PKC β promoter and lengths of deletion constructs

Figure 20. Effect of high glucose on PKC β deletion constructs

Figure 21. Construct D quenches PKC β promoter activity at 10h post-synchronization corresponding to S phase

Figure 22. Northern blot analysis of PKC β II mRNA in A10 cells treated with actinomycin D in the presence or absence of high glucose

Figure 23. *In vitro* assay for RNA stability

Figure 24. *In vitro* assay for RNA stability.in the presence of EDTA

Figure 25. A schematic representation of the PKC β as deduced from cDNA sequence analysis

Figure 26. High glucose destabilizes PKC β II mRNA

Figure 27. PKC β II cDNA (350 bp) sequence

Figure 28. PKC β II cDNA (350 bp) restriction sites map

Figure 29. Effect of glucose and insulin on PKC β II mRNA in aorta smooth muscle cells

Figure 30. Glucosamine does not affect PKC β II mRNA stability

Figure 31. Effect of glucose metabolites on PKC β II mRNA stability

Figure 32. Effect of cycloheximide on glucose-induced PKC β II destabilization

Figure 33. RT-PCR analysis of PKC β I and - β II mRNA after okadaic acid treatment

Figure 34. The p β G-PKC β II chimeric minigene

Figure 35. The p β G-PKC β II chimeric minigene is destabilized by high glucose

Figure 36. Half-life analysis of p β G-PKC β II mRNA

Figure 37. Schematic of the RNA probes used for the RNA EMSAs

Figure 38. RNA electrophoretic mobility shift assay using full length PKC β II mRNA probe

Figure 39. A cytosolic factor binds to a glucose-regulated element present in the PKC β II coding region

Figure 40. No RNA protein binding observed using RNA probe C

Figure 41. UV cross-linking analysis of the RNA-protein binding complex

Figure 42. PKC β II mRNA sequence and RNA secondary structure analysis

Figure 43. PKC β II mRNA sequence linearized at 175 bp with *Bgl* II and RNA secondary structure analysis

Figure 44. PKC β II mRNA sequence linearized at 137 bp with *Hpa* I and RNA secondary structure analysis

Figure 45. Diagram of 3' exons encoding PKC β I and PKC β II via exon inclusion/exclusion and regions of PKC β II exon involved in destabilization of mRNA.

Figure 46. Restriction map of 3' region of PKC β II exon with portions of 3' and 5' flanking exons to be cloned downstream of the cDNA of interest.

Detailed Description

Regulatable vectors for gene expression are often not reliable since they can be "leaky". They usually consist of systems where the gene of interest is cloned downstream of a minimal viral promoter fused to copies of the tetracycline operator. The promoters used with these repressor sequences are, however, not totally repressed in many cells. By engineering a construct that is also regulated at the post-transcriptional level, full repression of such a promoter could be achieved in a wider variety of cells. We propose that by inserting instability sequences downstream of an inserted cDNA, genes can be further regulated using high extracellular concentrations of glucose or non-metabolized analogues. Both Tet and Retroviral Tet Systems (Clontech) show promise for regulating transcription of genes in cells. The ecdysone-inducible expression system derived from *Drosophila* is also commercially available (Invitrogen) and may have even lower basal activity in mammalian cells. Basal activity of the tetO.HCMC IE promoter is highly variable when tested in several cell lines. Although the promoter was repressed in HeLa and PC12 cells, basal levels were 10-30 fold higher in BHK cells. This high basal activity limits the use of the tetracycline-repressed promoter. If a construct could be engineered that was also regulated at the post-transcriptional level, full repression of such a promoter could be achieved in a wider variety of cells. There are several inducible promoters available, however, no one has developed a system to regulate gene expression at the post-transcriptional level. The post-transcriptional regulation of mRNA destabilization of a gene is another possibility for designing regulatable gene expression

constructs. If the cDNA can be destabilized by a non-toxic nutrient or analogue, then expression can be stabilized when the analogue is withdrawn.

ABBREVIATIONS

AoSMC	Aorta smooth muscle cells
aPKC	Atypical PKC
ARE	Adenosine-uridine rich element
Ca ⁺²	Calcium
CAT	Chloramphenicol acetyltransferase
cDNA	Complementary DNA
ChoRE	Carbohydrate Response element
cPKC	Conventional PKC
CRE	cAMP-responsive element
CREB	cAMP-responsive element-binding protein
DAG	Diacyl glycerol
DMEM	Dulbecco's modified eagle's medium
DPBS	Dulbecco's phosphate-buffered saline
DRB	5,6-dicholoro-1-β-D-ribofuranosylbenzimidazole
DTT	Dithiothreitol
EMSA	Electrophoretic mobility shift assays
ERK	Extracellular signal-regulated kinase
FBS	Fetal bovine serum

FFA	Free fatty acids
HEPES	N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
HPV	Human papillomavirus
IGF	Insulin-like growth factor
IL-2	Interleukin-2
IP ₃	Phosphatidylinositol 1,4,5-trisphosphate
IRE	Iron responsive element
IRP	Iron regulatory protein
JAK	Janus kinase
JNK	c-jun NH ₂ -terminal kinase
L-PK	L-pyruvate kinase
Lyso PC	Lysophosphatidyl choline
MAPK	Mitogen-activated protein kinase
Mek	MAP kinase kinase
MOPS	3-(N-morpholino)propanesulfonic acid
mRNA	Messenger RNA
NaCl	Sodium chloride
NGF	Nerve growth factor
nPKC	Novel PKC
oxLDL	Oxidized low density lipoprotein
PC	Phosphocholine
PI3 kinase	Phosphoinositide-3-kinase
PIP ₂	Phosphatidylinositol 4,5-bisphosphate

PKC	Protein kinase C
PLA ₂	Phospholipase A ₂
PLC	Phospholipase C
PMSF	Phenylmethylsulfonyl fluoride
PNE	Post-nuclear extract
PP1	Type-1 phosphatase
PP2	Type-2 phosphatase
PPAR	Proliferating-activated receptor
PRK	PKC-related kinases
PS	Phosphatidyl serine
PTP	Protein tyrosine phosphatases
RACK	Receptor for activated PKC
RICK	Receptor for inactive PKC
Rsk	Ribosomal S6 kinase
RTK	Receptor tyrosine kinase
SmGM	Smooth muscle growth medium
STATs	Signal transducers and activators of transcription
TF	Transcriptional factors
TPA	12-O-tetradecanoylphorbol-13-acetate
UPAR	Urokinase-type plasminogen activator receptor
UTR	Untranslated region
VSMC	Vascular smooth muscle cells
Zn ⁺²	Zinc

Materials and Methods

Cell culture

The vascular smooth muscle cell line (A10, ATCC CRL 1476), derived from rat aorta, was grown in Dulbecco's modified Eagle's media (DMEM with 5.5mM glucose) containing 10% fetal bovine serum (FBS) and 100 units penicillin G and 100 µg streptomycin sulfate/ml at 37°C in a humidified 5% CO₂, 95% air atmosphere in either 6-well plates (for promoter studies, Western blot analysis, [³H]-thymidine uptake assay) or 100-mm plates (for Northern blot analysis, RNA stability assay). Cells were grown to >90% confluency and media was changed every 4 days. Cell synchronization was achieved by serum deprivation (0.5% FBS) for 48 hours (see, for example, Ross, R., C. Nist, B. Kariya, M. J. Rivest, E. Raines, and J. Callis. 1978. Physiological quiescence in plasma-derived serum: Influence of platelet derived growth factor on cell growth in culture. *J. Cell. Physiol.* 97:497-508).

Primary cultured human aortic smooth muscle cells (AoSMC) (Clonetics, San Diego, CA) were grown in SmGM (Clonetics) medium containing 5.5mM glucose, 5% FBS, 10 ng/ml human recombinant epidermal growth factor (hEGF), 390 ng/ml dexamethasone, 50µg/ml gentamicin, and 50 ng/ml amphotericin-B at 37°C in a humidified 5% CO₂, 95% air atmosphere. Cells were grown to >90% confluency and medium was changed every 5 days.

Materials

The isotopes [α - 32 P]dCTP and [α - 32 P]UTP (specific activity 3000Ci/mmol) were purchased from ICN Biochemicals. Oligo probe labeling kit (Prime-a-Gene) was purchased from Promega. Riboscribe T7 RNA Probe Synthesis kit and Ampliscribe T7 Transcription kit were purchased from Epicenter Technologies. RNase A, RNase T1, heparin, RNase inhibitor were purchased from Sigma. All other biochemicals were purchased from the usual vendors as noted. Inhibitors for the signaling pathways were used as described in the results. Cycloheximide (20mM), PD98059 (20 μ M), Okadaic acid (20nm), AG490 (5 μ M), rapamycin (1mM), herbimycin A (1 μ M) and LY 294002 (20 μ M) were obtained from Calbiochem. CGP41251 (5 μ M) was a gift from Dr. Dorian Fabbro, Ciba-Geigy (Basel, Switzerland).

Calcium-phosphate transfections

For promoter studies, A10 cells were grown and synchronized in 6-well plates. Three hours prior to transfections, fresh medium (DMEM containing 10% fetal bovine serum) was substituted on A10 cells. p β G or p β G-PKC β II expression vectors were transfected with the calcium-phosphate-DNA precipitate. Following overnight incubation, calcium phosphate-DNA precipitate was washed off with 1X Dulbecco's phosphate buffered saline (DPBS) and replaced with fresh medium. For stably-transfected cell selection, 0.7mg/ml G-418 was added to the media. It was changed every 4 days and 10-14 days later, the colonies were pooled and maintained in DMEM (10% FBS) with 0.2mg/ml G-418.

mRNA half-life determination

A10 cells were pre-treated with actinomycin D (5 μ g/ μ l) for about 30 minutes, followed by the addition of glucose (25mM) to the glucose-treated plates. RNA samples were isolated from control (5.5mM glucose) and glucose-treated (25mM glucose) dishes at 0h, 2h, 4h, or 6h. Northern blot analysis was then performed on about 10 μ g of the total RNA as described below.

In separate experiments, p β G-PKC β II stable transfectants were plated into 100mm dishes. 5,6-dichloro-1- β -D-ribofuranosylbenzimidazole (DRB) (50 μ g/ml) dissolved in 95% ethanol was added to the plates and the 0h RNA sample was isolated. Glucose (25mM) was added to the glucose-treated plates. RNA samples were isolated from control (5.5mM glucose) and glucose-treated (25mM glucose) p β G-PKC β II plates at 2h, 4h, and 6h. In a separate control, an equivalent amount of 95% ethanol was added.

Isolation of RNA and Northern Blot Analysis

Total cellular RNA was isolated from 100-mm plates using Tri-Reagent (Molecular Research Center, Inc.). RNA samples (10 μ g) were prepared in formamide, formaldehyde and 1 X 3-(N-morpholino)propanesulfonic acid (MOPS), and fractionated on 1.2% agarose-formaldehyde gels. Ethidium bromide was added in the loading buffer for visualization and quantitation of 18S and 28S RNA. After fractionation, the integrity and loading of RNA was assessed under UV light (23,24). The size-fractionated RNA was then capillary transferred to Hybond membranes (Amersham), and cross-linked to membranes by baking at 80°C in a vacuum oven for 2 hours. Membranes were hybridized

overnight at 42°C with 2×10^7 cpm of the full length PKC β cDNA probe or β -globin probe (labeled with [32 P] dCTP by nick translation as described (25)) per ml of hybridization buffer (5X SSC, 5X Denhardt's solution, 0.5% (w/v) SDS, 50% (v/v) formamide). Membranes were washed with high stringency conditions (1 X SSC, 0.1% SDS for 15 minutes at 42°C followed by 0.11 X SSC, 0.1% SDS for 15 minutes at 42°C), and quantitated using Molecular Dynamics Phosphoimaging System. In experiments, where mentioned, membranes were exposed to X-ray film and the autoradiograms were quantitated densitometrically.

RNA stability assay

To prepare post-nuclear extracts (see, for example, Wager, R. E. and R. K. Assoian. 1990. A phorbol ester-regulated ribonuclease system controlling transforming growth factor B1 gene expression in hematopoietic cells. *Mol. Cell. Biol.* 10:5983-5990), synchronized A10 cells, re-initiated to proliferate with DMEM + 10% FBS were treated with either 5.5mM or 25mM glucose for 2 h to 24 h, then washed and collected in ice-cold 1 X DPBS. The cellular pellet was re-suspended in extract buffer containing 0.01M Tris-HCl, 0.15M NaCl, 0.5% Nonidet P-40, leupeptin (10 μ g/ml) and aprotinin (10 μ g/ml) incubated on ice for 10 minutes and carefully layered over extract buffer containing 24% sucrose. Samples were centrifuged over a sucrose gradient at 10,000xg for 20 minutes at 4°C. Post-nuclear extract was separated, stored on ice and aliquots taken for protein concentration using Bradford protein assay (see Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72:248-254). Total RNA (10 μ g)

from A10 cells, was incubated with 2.7% (vol/vol) of the post-nuclear extracts for 30 minutes at 4°C in 50 µl (final volume) of extract buffer. When specifically noted, 50mM EDTA was added to the reactions as a control to inhibit nuclease activity. The reactions were terminated by phenol-chloroform extraction, supplemented with 10 µg yeast tRNA as carrier and precipitated with ethanol. RNA was fractionated on 1.2% formaldehyde-agarose gels and Northern blot analysis was carried out with full length PKCβ cDNA probe. The assay and analyses was repeated at least three times with separate post-nuclear extracts to assess and confirm reproducibility.

Reverse Transcriptase-Polymerase Chain Reaction

Total RNA was isolated from control (5.5mM glucose) or glucose-treated (25mM glucose) A10 cells and 2 µg was used to synthesize first strand cDNA using an Oligo(dT) primer and Superscript II reverse transcriptase (Life Technologies Pre-amplification Kit). The upstream sense primer corresponded to the C4 kinase domain common to both PKCβI and PKCβII (5' CGTATATGCGGCCGCGTTGTGGGCCTGAAGGGG 3') and the downstream antisense primer was specific for PKCβI (5' GCATTCTAGTCGACAAGAGTTTGTCTAGTGGGAG 3') (Chalfant *et al.*, 1995, pp.13326-13332.). These primers detect inclusion of the PKCβII exon in the mature mRNA as well as PKCβI mRNA. Sense and antisense primers for β-actin (#5402-3) were obtained from Clontech. PCR was performed using ampliTaq Gold DNA polymerase from Perkin Elmer (#N808-0240) on 10% of the reverse transcriptase reaction product. Following 35 cycles of amplification in a Biometra Trioblock thermocycler (PKCβI and -βII: 95°C, 30 sec; 64°C, 2 min for 35 cycles; and for β-actin: 94°C, 1 min; 58°C, 1 min;

and 72°C, 3 min for 35 cycles), 25% of the PCR reaction was resolved on a 1.2% agarose gel. Bands were observed under UV light and photographed.

For the stability reporter system, β -globin primers were designed. The sense primer was (5' GCATCTGTCCAGTGAGGAGAA 3') while the antisense primer for β -globin was (5' AACCAGCACGTTGCCCAGGAG 3'). PCR was performed using ampliTaq Gold DNA polymerase from Perkin Elmer (#N808-0240) on 10% of the reverse transcriptase reaction product. Following 25 cycles of amplification in a Biometra Trioblock thermocycler (94°C, 1 min; 58°C, 1 min; and 72°C, 3 min for 25 cycles), 25% of the PCR reaction was resolved on a 1.2% agarose gel. Bands were observed under UV light and photographed. The expected size of the amplified product was 320 bp.

Synthesis of pCR-blunt-PKC β II

Total RNA was isolated from A10 cells and 10 μ g of the RNA was used in the RT-PCR reaction (as described above). The amplified products were separated on 1.2% agarose gel. The PKC β II-specific band of 404bp was cut from the gel and purified using QIAquick gel extraction kit (Qiagen). The PKC β II cDNA was cloned into the vector pCRblunt (purchased from Invitrogen, Inc.) and used in the sequencing reaction. By sequence analysis, it was confirmed that the PKC β II mRNA resulted from the inclusion of the 216bp PKC β II specific exon via alternative splicing of the PKC β pre-mRNA.

β -globin cDNA probe preparation

The pRSV- β G vector (obtained from N. P. Curthoys, Colorado State University) (Hansen *et al.*, 1996, pp. F126-31) was restricted with *HindIII* and *BglII* to obtain a

507bp fragment, which was purified from agarose gel using QIAquick gel extraction kit (Qiagen). 25ng of the probe was labeled with [α - 32 P]dCTP using Prime-a-Gene (Promega) to a specific activity of 10^9 d.p.m.

Synthesis of p β G-PKC β II chimeric minigene

The parent vector, p β G, was obtained from N. P. Curthoys (see Hansen W.R., Barsic-Tress N., Taylor L., and Curthoys N.P. The 3'-nontranslated region of rat renal glutaminase mRNA contains a pH-responsive stability element. [Journal Article] American Journal of Physiology. 271(1 Pt 2):F126-31, 1996 Jul), Colorado State University. The p β G contains the strong viral promoter derived from the long terminal repeat of the Rous sarcoma virus followed by the transcriptional start site, the 5'-nontranslated region, the entire coding sequence, and two introns from the rabbit cloning gene; a multicloning site containing four unique restriction sites; and the 3'-nontranslated region and polyadenylation site of the bovine growth hormone. PKC β II cDNA was cloned earlier into the pCR-Blunt vector (Invitrogen) and to expedite the procedure, it was digested with *SpeI* and *XbaI*, extracted from the gel (Qiagen's QIAquick gel extraction kit) and purified. The PKC β II cDNA was subcloned in frame with the β -globin reading frame into the *SpeI* and *XbaI* sites of the multicloning region of p β G vector (figure 34). The 3'-nontranslated region and polyadenylation site of the bovine growth hormone were maintained in the resultant p β G-PKC β II minigene. The construct was verified by restriction mapping and dideoxynucleotide sequencing.

Transcription vectors

The 404bp PKC β II product was obtained by PCR amplification using sense primer to the upstream PKC β common C4 domain (5' CGTATATGCGGCCGCGTTGTGGGCCTGAAGGGG 3') and anti-sense primer to β IV5 domain (5' GCATTCTAGTCGACAAGAGTTTGTCAAGTGGGAG 3') such that the exon-included PKC β II mRNA was amplified. This PKC β II cDNA piece was cloned into the pCR-Blunt vector (Invitrogen) such that sense transcripts could be generated from the upstream T7 RNA polymerase promoter. A 410 bp β -globin segment cloned into the pCR-Blunt vector was used as a non-specific competitor probe.

In vitro transcription

The RNA probes were generated by consecutive restriction digestion of the pCR-Blunt-PKC β II vector. Probe A was the full length PKC β II insert linearized with BamHI; probe B was PKC β II linearized at 175bp with BglII within PKC β II exon such that the PKC β I-specific exon was eliminated; probe C was linearized at 137bp with HpaI which cuts within the PKC β II-specific exon; probe D was linearized at 102bp with SspI which cuts within the PKC β II-specific exon; probe E was linearized at 45bp with FokI which cuts within the C4 exon. After digestion, the probes were purified and their sizes and linearity were confirmed on agarose gels and further used for in vitro transcription with Ampliscribe kit (Epicenter) for competitor unlabeled probes or with Riboscribe kit (Epicenter) for transcribing labeled RNA probes according to the manufacturer's instructions.

Cytoplasmic extract (S100) preparation for RNA Electrophoretic Mobility Shift Assay

In brief, A10 cells incubated in 5.5mM glucose (normal) or 25mM glucose (high glucose) for 4 h were washed with 1 X DPBS, scraped, collected and centrifuged at 3000rpm for 10 min. The packed cells were re-suspended in hypotonic buffer (10mM HEPES, pH7.9 at 4°C; 1.5mM MgCl₂; 10mM KCl; 0.2mM PMSF; 0.5mM DTT; 10μM leupeptin; 10μM antipain), allowed to swell for 10 min on ice, and homogenized in a Dounce homogenizer with 60 strokes using a type B pestle. The nuclei was pelleted by centrifuging at 3300 X g for 15 min, and the cytoplasmic extract was mixed with 0.11 vol of cytoplasmic buffer (0.3M HEPES, pH7.9 at 4°C; 1.4M KCl; 0.03M MgCl₂). After centrifugation for 1 h in Beckman type 50 rotor at 40,000 rpm, the supernatant was aliquoted, frozen in liquid nitrogen and stored at -80°C. An aliquot was used to determine the protein concentrations using the Bradford method (Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantites of protein utilizing the principle of protein-dye bindingno title. Anal. Biochem. 72:248-254) for protein assay.

RNA Electrophoretic Mobility Shift Assay (EMSA)

With modifications to methods described by Brewer, G. and J. Ross. 1989. Regulation of c-myc mRNA stability in vitro by a labile destabilizer with an essential nucleic acid component. Mol Cell Biol 9:1996-2006; Amara, F. M., J. Sun, and J. A. Wright. 1996. Defining a Novel cis-Element in the 3'-Untranslated Region of Mammalian Ribonucleotide Reductase Component R2 mRNA. The Journal of Biological Chemistry

271, No. 33:20126-20131) and Amara, F. M., G. M. Smith, T. I. Kushak, T. L. Takeuchi, and J. A. Wright. 1996. A cis-trans interaction at the 3'-untranslated region of ribonucleotide reductase mRNA is regulated by TGF- β 1, TGF- β 2 and TGF- β 3. Biochemical and Biophysical Research Communications 228 (2): 347-351) cytoplasmic extracts from A10 cells (normal and high glucose) containing 3 μ g protein were incubated with 3 μ g yeast tRNA, 10 units of RNase inhibitor in a final volume of 10 μ l RNA shift buffer (12mM HEPES, pH7.9, 10mM KCl, 10% glycerol, 5mM EDTA, 5mM DTT, 5mM MgCl₂) for 10 min at room temperature. 100 to 300 fold excess specific cold competitors or 100-fold excess non-specific cold competitor were added to the binding-reactions and incubated for 5 min at room temperature. ³²P labeled RNA probes A, B, C or D (described above) to a specific activity of $\sim 1 \times 10^6$ / μ g were added and incubated for 20 min at room temperature. 100 U of RNaseT1 was added and further incubated for 15 min at room temperature, followed by the addition of 5mg/ml heparin to reduce nonspecific binding, for 10 min on ice. Samples were separated on a 10% polyacrylamide gel in 0.5X TBE buffer. Gels were dried and exposed to Molecular Dynamics Phosphoimaging Screen.

UV cross-linking of RNA-protein complexes

RNA-protein binding reactions were carried out as described above for the RNA EMSA. Following heparin addition, the samples were transferred to a 96-well plate, irradiated for 10 min in Stratalinker (Stratagene) on ice. Laemmli's buffer was added to the sample which was then boiled for 5 min and electrophoresed in a 10% SDS-

polyacrylamide gel. Gels were dried and exposed to Molecular Dynamics Phosphoimaging Screen.

Results

PKC β II protein levels decreased when A10 cells were exposed to 25mM glucose

To better understand the biochemical mechanism underlying the acute effects of high glucose exposure on PKC β expression in aortic vascular smooth muscle cells, protein levels of PKC β I and β II were determined in synchronized A10 cells. Cell growth synchronization was achieved by serum deprivation for 48 hours as described in methods, and following synchronization, medium on A10 cells was replaced with DMEM containing 10% FBS to re-initiate cell proliferation and incubated with high (25mM) or normal (5.5mM) glucose. Over a twenty-four hour period, protein was extracted at various time points from cells re-initiated by serum addition to proliferate. It appeared that as cells progressed through the cell cycle, the expression of PKC β II appeared to be cell cycle associated, with highest levels of protein expression observed at 6 and 18 hours and lowest levels occurring at 14 hours. PKC β II protein levels in cells treated with high glucose decreased by 55% within first 6 hours and remained low following 14 hours of continuous high glucose treatment and began to increase at 18 hours (Figure 17). No significant changes in PKC β I protein levels were detected between high and normal glucose (

Figure 16). To check the specificity of high glucose to down-regulate PKC β II, western blot analysis was repeated using primary antibodies to PKC α and PKC ϵ .




Figure 16. PKCβI protein levels remain unaltered in the presence of high glucose.

A10 cells were synchronized by culturing the cells in DMEM containing 0.5% FBS for 48 hours. To re-initiate the cell cycle, A10 cells were incubated in DMEM with 10% FBS containing 5.5mM glucose (control cells) or 25mM glucose (hyperglycemic condition) for indicated periods up to 18 hours. Western blot analysis was carried out on cell lysates using anti-PKCβI as primary antibody. Proteins were detected using enhanced chemiluminescence (ECL, Amersham) as described in methods. Densitometric scanning was used to quantify PKCβI bands from the blots. The graph depicts PKCβI protein levels in the presence of 25mM glucose plotted as the percent of the total PKCβI levels present in the respective control (5.5 mM glucose) cells. Data are representative of at least 5 separate experiments.

Again, no significant changes in PKC α or - ϵ protein levels were detected between high and normal glucose treatments (data not shown).




Figure 17. PKC β II protein levels decreased by 55% in the presence of glucose.

A10 cells were synchronized by culturing the cells in DMEM containing 0.5% FBS for 48 hours. To re-initiate the cell cycle, A10 cells were incubated in DMEM with 10% FBS containing 5.5mM glucose (control cells) or 25mM glucose (hyperglycemic condition) for indicated periods up to 18 hours. Western blot analysis was carried out on cell lysates using (a) anti-PKC β I and (b) anti-PKC β II as primary antibodies. Proteins were detected using enhanced chemiluminescence (ECL; Amersham) as described in methods. Densitometric scanning was used to quantify PKC β I and PKC β II bands from the blots. The graphs depict PKC β I and PKC β II protein levels in the presence of 25mM glucose plotted as the percent of the total PKC β I and PKC β II levels present in the respective control (5.5 mM glucose) cells. Data are representative of at least 5 separate

Thus, the down-regulation by acute glucose appeared specific for the PKC β II isoform and did not affect the other PKC isozymes.

Hyperglycemic conditions markedly reduce PKC β (I+II) mRNA in A10 cells

To determine the acute effects of hyperglycemia on PKC β gene expression, steady state levels of PKC β mRNA were examined in synchronized A10 cells (by serum deprivation for 48 hours as described in methods) that were re-initiated to proliferate by changing the medium to DMEM containing 10% FBS and incubated for 15-18 hours with either high (25mM) or normal (5.5mM) glucose. Cells incubated with 25mM mannitol were used as osmotic controls. Total RNA was extracted and the mRNA transcript levels were detected using a full length PKC β cDNA probe which would cross-hybridize with both PKC β I and PKC β II mRNAs. As shown in Figure 18, a 60-75% decrease in PKC β (I+II) mRNA levels were observed in cells treated overnight with high glucose (25mM). The mRNA levels in the control cells (5.5mM glucose) and osmotic control cells (mannitol-treated) remained unchanged. This suggested that high glucose down-regulated PKC β (I+II) gene expression. Since protein analysis following high glucose exposure indicated a decrease only in PKC β II levels, it was assumed that the northern blot analysis reflected a down-regulation of PKC β II mRNA while PKC β I mRNA remained unaltered. Since PKC β II is the product of PKC β mRNA alternatively splicing, the possibility existed that transcriptional as well as post-transcriptional controls were altered by high glucose.




Figure 18. Down regulation of PKC β (I+II) mRNA by glucose.

Total RNA was extracted from A10 cells that were synchronized in culture with DMEM containing 0.5% FBS for 48 hours, then re-initiated to proliferate with DMEM + 10% FBS, and incubated for 15-18 h in medium (DMEM + 10% FBS) containing 5.5mM glucose (lane 1), 25mM glucose (lane 2) or 25mM mannitol (lane 3) as indicated. RNA (10 μ g) was fractionated on 1.2% agarose-formaldehyde gel, 28S and 18S rRNA were visualized to ensure equal loads of RNA (lower panel), capillary transferred to Hybond membrane (Amersham) and probed with a 32 P-labeled PKC β cDNA probe that would detect PKC β (I+II) mRNA as described in methods. Following exposure to X-ray film, the autoradiogram was analyzed densitometrically. A 60-75% decrease in PKC β (I+II) mRNA (3.5Kb) was observed under high glucose conditions. Data is representative of an experiment repeated with similar results on at least 4 occasions.

Glucose quenches PKC β promoter activity

Our studies indicated that PKC β II protein levels “cycled” with synchronized A10 cells during a 24 hour period post re-initiation of the cell cycle with serum (Yamamoto *et al.*, 1998, pp.349-358). We chose first to systematically study the effect of high glucose on PKC β promoter activity in synchronized A10 cells. Glucose may be exerting its effect on PKC β gene expression through a response element located in the common promoter upstream of the transcription start site as reported with L-PK and S14 gene expression in hepatocytes. Since PKC β is a low copy gene, nuclear run-on assays were not a practical approach to examine transcriptional regulation. Hence, the PKC β -CAT expression plasmids cloned by Dr. Ohno (Yokohama College of Medicine) (Niino, Y., S., S. Ohno, and K. Suzuki. 1992. Positive and negative regulation of the transcription of the human protein kinase C β gene. *J. Biol. Chem.* 267:6158-6163) were used to study transcriptional regulation of PKC β gene expression by glucose. PKC β promoter constructs with successive deletions of the 5' region cloned in front of a promoterless chloramphenicol acetyltransferase (CAT) as the reporter gene were transiently transfected into A10 cells (Figure 19). pSV- β -Galactosidase was co-transfected with the CAT constructs to normalize the efficiency of transfection. Simultaneous positive and negative controls were carried out as described previously.

Transcriptional repression of PKC β promoter by transcription factors in response to high glucose was anticipated. However, in A10 cells incubated with high glucose (25mM) for six hours, a moderate decrease or quenching in the PKC β promoter activity of constructs A (-4.1kb to +179CAT), C (-674 to +179CAT) and D (-411 to +179CAT)




Figure 19. Map of PKC β promoter and lengths of deletion constructs.

5' deletion mutants of PKC β gene cloned in the PKC β -CAT plasmid were obtained from Dr. S. Ohno (Yokohama College of Medicine). The positions of *cis*-acting regulatory elements on the promoter region of PKC β gene are indicated. Construct A (-4.1kb to +179 CAT), construct C (-674 to +179 CAT), construct D (-411 to +179 CAT) and construct E (-234 to +179 CAT) were transiently transfected into synchronized A10 cells.




Figure 20. Effect of high glucose on PKC β deletion constructs.

Constructs A, C, D, and E, as designated above, were transiently transfected into A10 cells synchronized for 48 hours in DMEM + 0.5% FBS, re-initiated to proliferate in DMEM + 10% FBS, using calcium phosphate-DNA precipitate along with β -galactosidase (1 μ g) to normalize transfection efficiency. After overnight transfection, the cells were washed with DPBS and placed in fresh medium (DMEM + 10% FBS) containing either 5.5mM or 25mM glucose. Cells were extracted after 6h and relative CAT/ β -galactosidase activity was measured in control (5.5mM glucose) and glucose (25mM)-treated cells. Construct D showed maximum quenching of PKC β promoter activity. This graph represents relative CAT/ β -galactosidase activity for 3 individual experiments performed in duplicate.

was observed (Figure 5). Construct E (-234 to +179CAT) showed no quenching with glucose indicating that a putative carbohydrate response element had been deleted. Construct E contains the basal response elements required for promoter activity and was not affected by glucose concentrations. Thus construct D contained the elements involved

in maximum quenching of promoter activity, presumably within a 177 bp region which was deleted in construct E. In parallel experiments, a control with 100nM TPA increased the promoter activity ten-fold in all constructs. This confirmed the response of PKC β basal promoter element with phorbol esters.

In the case of transcriptional repression, DNA binding is inhibited by repressors blocking the binding site for a factor or forming a non-DNA-binding protein-protein complex resulting in inhibition of transcription. The reduction in promoter activity observed here, however, did not account for the dramatic down-regulating effect of glucose on total PKC β mRNA. If glucose effects were mediated exclusively at the transcriptional level, total repression would have occurred. The reduction in promoter activity observed here is most likely explained as a quenching effect that involves interfering with transcriptional activation by a DNA-bound factor. An example of transcriptional quenching is illustrated by the yeast factor GAL80, which inhibits gene activation by the positively acting GAL4 protein in the regulation of galactose in yeast. Since the extent of quenching of the PKC β promoter by glucose varied depending on the time points examined, the results suggested that as cells progress through the cell cycle, high glucose regulation of PKC β gene expression may be cell cycle mediated. Simultaneous cell cycle studies and promoter activity of construct D (-411 to +179 CAT) in high glucose were determined. The results demonstrated an increase in the percentage of cells going into S phase in high glucose implying that quenching of PKC β transcription may be related to cell cycle progression (Figure 21).




Figure 21. Construct D quenches PKC β promoter activity at 10h post-synchronization corresponding to S phase.

Construct D, as described in Figure, was transiently co-transfected with β -galactosidase into synchronized A10 cells. Promoter activity in control (5.5mM glucose) and glucose (25mM)-treated cells following 6-24 hours of treatment was calculated as relative CAT/ β -galactosidase units. Maximum quenching by high glucose of PKC β promoter construct D (-411/+179CAT) was observed at 10 h which is the peak of S phase as determined by ^3H -thymidine uptake studies as described (below). Error bars indicate \pm S.E.M. Data shown is the mean of \pm SE for triplicate determinations of an experiment that was repeated on three separate occasions with similar results. (* indicates significance at $p < 0.05$).

PKC β mRNA is destabilized by glucose

Since the quenching of PKC β promoter activity by acute high glucose did not account for the 60-75% reduction in PKC β mRNA levels as observed by northern blot analysis (Figure 18), the major effect of glucose may be exerted post-transcriptionally. However, high glucose also diminished PKC β II protein levels, suggesting that high glucose could affect the stability of the PKC β II transcript at the post-transcriptional level. Northern blot analysis of PKC β (I+II) mRNA level (see methods) was performed on total RNA from synchronized A10 cells. Upon re-initiation of proliferation by DMEM + 10% FBS, A10 cells were pre-treated with actinomycin D for 30 minutes followed by incubation with normal or high glucose. The mRNA levels were detected using the full-length PKC β II cDNA probe which recognizes both PKC β I and PKC β II mRNA. A10 cells exposed to high glucose showed a decrease in PKC β (I+II) mRNA levels within 2 hours of treatment (Figure 22) and levels further decreased to 60% of control by 6 hours. Thus, the results suggested that post-transcriptional destabilization of PKC β II mRNA by glucose was also occurring.

***In vitro* assay for mRNA destabilization**

To assess the involvement of a nuclease activity in the destabilization of PKC β mRNA by glucose, an *in vitro* RNA stability assay was performed (see, for example, Wager, R. E. and R. K. Assoian. 1990. A phorbol ester-regulated ribonuclease system controlling

transforming growth factor B1 gene expression in hematopoietic cells. Mol. Cell. Biol.

10:5983-5990). A10 cells incubated with 5.5mM or 25mM glucose for 2 h, 6h, 18h and




Figure 22. Northern blot analysis of PKC β II mRNA in A10 cells treated with actinomycin D in the presence or absence of high glucose.

A10 cells were synchronized by maintaining them in DMEM + 0.5% FBS for 48 hours, followed by re-initiation of cell proliferation in DMEM + 10% FBS. Synchronized A10 cells were pre-treated with actinomycin D (5 μ g/ml) for 30 minutes in DMEM + 10% FBS. At time zero, glucose was added such that the medium contained 5.5mM glucose (**Con**) or 25mM glucose (**Glc**). Total RNA was extracted from 0 to 6 h, and then 10 μ g of RNA was fractionated on 1.2% agarose-formaldehyde gels, 28S and 18S rRNA were visualized to ensure equal loads of RNA (lower panel), capillary transferred to Hybond membrane (Amersham), and probed with a 32 P-labeled PKC β cDNA probe that detects PKC β (I+II) mRNA as described in methods. Images of the 3.5 kb transcript were quantitated using Molecular Dynamics Phosphoimaging system and are representative of three individual experiments. The graph depicts PKC β (I+II) mRNA levels, in the presence of 25mM glucose plotted as the percent of the total PKC β (I+II) mRNA levels present in the control (5.5 mM glucose) cells. A 60% decrease (* indicates significance at $p < 0.05$) in PKC β (I+II) mRNA is seen at 6 hours with glucose-treated cells.

24h were used to prepare control post-nuclear extracts (control PNE) or glucose-treated post-nuclear extracts (glucose PNE). Total RNA isolated from untreated A10 cells was incubated with 2.7% (vol/vol) post-nuclear extracts or glucose-treated post-nuclear extracts from A10 cells in 50 μ l total volume of extract buffer. As a positive control, RNA incubated without post-nuclear extracts was used. A reaction with no RNA served as the negative control. Since involvement of divalent cations is a feature of some ribonucleases that regulate mammalian RNA turnover, EDTA was added to post-nuclear extracts to distinguish nuclease activity from cyclizing RNases and acid lysosomal RNase. Northern blot analysis was then performed to detect non-degraded PKC β (I+II) mRNA. Incubation of RNA with post-nuclear extracts from synchronized A10 cells treated with 25mM glucose for 2 hours and 6 hours showed 45% and 65% decreases, respectively, in PKC β (I+II) RNA levels while incubation for 18 hours and 24 hours showed 8% and 12% decreases, respectively, in PKC β (I+II) RNA levels (Figure 23). No degradation of RNA was observed in the presence of EDTA, either in the control or high glucose treated post-nuclear extracts (Figure 24). These results indicate the activation of a divalent cation-dependent nuclease activity by high glucose. The destabilization of PKC β (I+II) mRNA by glucose accounted for a significant down-regulation of PKC β II expression although these observations suggested that destabilization of PKC β II mRNA occurred as an early event in the regulation of mRNA processing by high glucose.




Figure 23. *In vitro* assay for RNA stability.

Post-nuclear extracts were prepared from A10 cells treated with either 5.5mM glucose (control cells) or 25mM glucose (glucose-treated cells) for 2, 6, 18 or 24 hours. Total RNA (previously extracted from synchronized A10 cells) was incubated for 30 minutes at 4°C with 2.7% (vol/vol) post-nuclear extracts from control (5.5mM glucose) or 25mM glucose-treated A10 cells in a 50μl total reaction volume. Northern blot analysis for PKCβ(I+II) mRNA was then performed on the RNA as described in methods. Images of the 3.5 kb bands were quantitated by phosphoimaging and are representative of four individual experiments with similar results. The graph shows the total PKC(βI+II) mRNA levels remaining after incubation with post-nuclear extracts from glucose-treated cells plotted as a percent of the total PKC(βI+II) mRNA in the respective control incubations with post-nuclear extracts from cells treated with 5.5mM glucose. Protein concentrations of control (5.5mM glucose) post-nuclear extracts (control PNE) and 25mM glucose-treated post-nuclear extracts (glucose PNE) at 2 hours were 2.5 mg/ml and 2.23 mg/ml respectively; at 6 hours, protein levels were 1.34 mg/ml and 1.34 mg/ml respectively; at 18 hours, levels were 1.3mg/ml and 1.25 mg/ml respectively; and at 24 hours, levels were 1.22 mg/ml and 1.27 mg/ml




Figure 24. *In vitro* assay for RNA stability.in the presence of EDTA

No degradation of total RNA by glucose-treated post-nuclear extract was observed when 50mM EDTA was added to the reaction mix as described above. Similar results were obtained in three separate experiments.

Specificity of mRNA destabilization by glucose

Since a full length PKC β cDNA probe was used for analysis of PKC β (I+II) RNA levels by the northern blot analysis, RT-PCR was performed on total RNA from A10 cells to determine the specificity of high glucose to down-regulate PKC β II mRNA rather than PKC β I mRNA. Previously, it had been demonstrated that mature PKC β II mRNA results from differential processing resulting in PKC β II exon inclusion into PKC β I mRNA transcript (Chalfant *et al.*, 1995, pp.13326-13332; Ono *et al.*, 1987, pp.1116-1120). Thus, the PKC β II transcript contains the PKC β I exon with the poly A tail and a common 3' untranslated region (Figure 25). Inclusion of the alternatively spliced exon encodes a stop codon such that the PKC β I exon facilitates poly-adenylation but the exon is not translated, thereby generating PKC β II protein. Primers were designed for the upstream common kinase region (C4) (-sense primer) and the PKC β I exon (-antisense primer) for simultaneous amplification of both PKC β I and - β II messages by RT-PCR. In control A10 cells (5.5mM glucose), both PKC β I and PKC β II PCR products were detected. Although, this assay is semi-quantitative, the ratio of PKC β II to PKC β I mRNA was about 2 to 1. In glucose-treated (25mM) A10 cells, PKC β II PCR product decreased >90% while PKC β I mRNA levels did not show any significant change. β -actin mRNA levels remained constant in both control and glucose-treated A10 cells (Figure 26). Thus, PKC β II mRNA was specifically destabilized in response to 25mM glucose.




Figure 25. A schematic representation of the PKCβ as deduced from cDNA sequence analysis.

The shaded blocks C1-C4 represent the conserved regions while V1-V5 blocks represent the variable regions. The regulatory and the catalytic domains are separated by V3, which serves as a hinge region. PKCβI and -βII, the alternatively spliced products of PKCβ pre-mRNA, diverge in their C-terminal sequence by 50 or 52 amino acids respectively. The enlarged area represents the genomic structure of the alternatively spliced V5 region. Introns are represented by lines and exons are represented by blocks. The arrows indicate the regions that correspond to the sense primer (the last common region (C4) for PKCβI and -βII) and antisense primer (to the βIV5 region) used for amplification of both PKCβI and -βII cDNAs simultaneously.




Figure 26. High glucose destabilizes PKCβII mRNA

RT-PCR was performed on total RNA isolated from A10 cells synchronized by serum starvation for 48 hours or from primary cultures of AoSMC from humans synchronized by serum starvation for 72 hours. Cells were re-initiated to proliferate by serum introduction to the basal medium and incubated with 5.5mM glucose (control) or 25mM glucose (glucose-treated) for 4 h. The first strand cDNA synthesized was amplified using a sense primer to the common, C4, domain and antisense primer to the PKCβI exon. The PCR product size was 187 bp for PKCβI; 404 bp for PKCβII and 550 bp for β-actin. PKCβII mRNA was decreased >95% by 25mM glucose treatment while PKCβI mRNA remained unchanged. No change was observed in the β-actin PCR products both in 5.5mM and 25mM glucose treated cells. Results are representative of an experiment repeated on five occasions.

To extend the physiological relevance of the down-regulation of PKC β II by high glucose, we repeated the RT-PCR described above using primary cultured aortic smooth muscle cells from humans (AoSMC CC2571, Clonetics Normal Human Cell System™). In high glucose medium (25 mM glucose), AoSMC showed a >95% decrease in PKC β II mRNA while PKC β I mRNA was not significantly affected. β -actin mRNA levels remained the same in both control (5.5 mM glucose) and glucose-treated (25 mM glucose) AoSMC (Figure 26). Since cells from human primary culture responded in the same manner, the A10 cells proved to be a reliable model for studying the effects of high glucose on PKC β gene expression in vascular smooth muscle cells.

PKC β II mRNA is generated via exon inclusion of the alternatively spliced PKC β pre-mRNA in VSMC

To verify that the amplified product was PKC β II cDNA, the 404bp band corresponding to the PKC β II cDNA was excised from the gel and cloned into the pCR-blunt vector.

```
5'TTTTAAACCAAAAGCTTTTTGGGCGAAACGCTGAAACTTC
GACCGGTTTTTCACCCGCCATCCACCAGTCCTAACACCTCC
GACCAGGAAGTCATCAGGAATATTGACCAATCAGAATTCTGA
AGGAU TTCCTTTGT TAACTCTGAATTTT TAAAACCCGAAGTC
AAGAGCTAGTAGATCTGTAGACCTCCGTCCTTCATTTCTGTC
ATTCAAGCTCACAGCTATCATGAGAGACAAGCGAGACACCT
CCAACTTCGACAAAAGTTCACCAGGCAGCCTGTGGAAGTGA
CTCCCACTGACAAACTCTGTGCGACTAGAATGCCCTGAATTC
TGCAGATATCCATCACACTGCG 3'
```

Figure 27. PKC β II cDNA (350 bp) sequence

Dideoxy sequencing and restriction digestion confirmed that the mature PKC β II mRNA was a result of a 216 bp exon inclusion via alternative splicing of the PKC β mRNA. The sequence for up to 350 bp is shown in

Figure 27 while the restriction sites map is depicted in **Figure 28**.




Figure 28. PKC β II cDNA (350 bp) restriction sites map.

PKC β II mRNA was destabilized when AoSMC cells were incubated with 25mM glucose

Insulin activates PKC and regulates the activity of glucose transporters (GLUT4) which are essential for regulated glucose uptake in quiescent smooth muscle cells. Since efficient transport into muscle cells is critical for glucose metabolism, we determined if insulin affected the stability of PKC β isozymes by high glucose. AoSMC were synchronized by serum starvation as described in methods and upon re-initiation of the cell cycle with SmGM containing 5% FBS, were treated with either 5.5mM glucose

(normal glucose), 25mM glucose (high glucose), 100nM insulin or 25mM glucose + 100nM insulin for 4 hours. Total RNA was isolated and products quantified as percent PKC β II present in the total PKC (β I+ β II) mRNA. Insulin did not destabilize PKC β I or PKC β II mRNA (Figure 29) but in the presence of high glucose and insulin, PKC β II mRNA was diminished by 60%. Thus insulin-stimulated PKC activation and glucose uptake was not associated with high glucose-induced destabilization of PKC β II mRNA. Insulin enables glucose uptake by the cells and results in the metabolism of glucose at a higher rate. This suggested that the buildup of free glucose in the cytosol may be essential for the destabilization of PKC β II mRNA by high glucose.

Metabolism of glucose to glucosamine is not required

Glucosamine, a metabolite of glucose and a product of the hexosamine pathway, has been implicated in the regulation of transforming growth factor- α gene expression in VSMC (Sayeski *et al.*, 1996, pp.15237-15243; McClain *et al.*, 1992, pp.8150-8154.) and other transcriptionally regulated genes. Although, glucosamine effects were primarily associated with transcriptional regulation, we investigated whether glucose also mediated its regulation of the PKC β II transcript stability via glucosamine. Synchronized A10 cells were treated with 5.5mM glucose (normal glucose), 25mM glucose or glucosamine (10mM in the presence of 5.5mM glucose) for 4 hours prior to RNA isolation and analysis (Figure 30). Glucosamine did not affect either PKC β I or - β II mRNA. Thus, further metabolism of glucose by the hexosamine biosynthetic pathway was not involved in the destabilization of PKC β II transcript by glucose.




Figure 29. Effect of glucose and insulin on PKC β II mRNA in aorta smooth muscle cells.

RT-PCR was performed on total RNA isolated from primary cultures of AoSMC from humans incubated with 5.5mM glucose (control), 25mM glucose (glucose-treated), 100nM insulin or 25mM glucose + 100nM insulin for 4 hours. The first strand cDNA synthesized was amplified using a sense primer to the common, C4, domain and antisense primer to the PKC β I exon. The PCR product size was 187 bp for PKC β I; 404 bp for PKC β II and 550 bp for β -actin. In control cells (lane 1), both PKC β I and - β II mRNA were detected; PKC β II mRNA was decreased >95% by 25mM glucose treatment while PKC β I mRNA remained unchanged (lane 2); 100nM insulin (lane 3) did not significantly affect either PKC β I or - β II mRNA; 25mM glucose + 100nM insulin (lane 4) PKC β II mRNA was decreased by 60%. No change was observed in the β -actin PCR products both in 5.5mM and 25mM glucose treated cells. Results are representative of an experiment repeated on five occasions.




Figure 30. Glucosamine does not affect PKCβII mRNA stability.

RT-PCR was performed on total RNA isolated from synchronized A10 cells incubated with 5.5mM glucose (control), 25mM glucose (glucose-treated) or 10mM glucosamine for 4 h. The first strand cDNA synthesized was amplified using a sense primer to the common, C4, domain and antisense primer to the PKCβI exon. The PCR product size was 187 bp for PKCβI; 404 bp for PKCβII and 550 bp for β-actin. Glucosamine did not destabilize PKCβI or -βII mRNA.

Glucose analogs mimic its effect

To further explore whether glucose is required to be metabolized in order to down-regulate PKCβII mRNA, we studied the effects of glucose analogs on PKCβI and -βII mRNA levels. A10 cells were synchronized by serum starvation as described supra and upon re-initiation of the cell cycle with DMEM containing 10% FBS, were treated with 5.5mM glucose (normal glucose), 25mM glucose, 25mM 2-deoxyglucose, 25mM 3-O-methylglucose or 5.5mM glucose + 19.5mM mannitol (osmotic control) for 4 hours. 2-deoxyglucose (2-DOG), is transported into the cell and phosphorylated to 2-

deoxyglucose-phosphate but cannot be metabolized further. See, for example, Patel, N. A., C. E. Chalfant, M. Yamamoto, J. E. Watson, D. C. Eichler, and D. R. Cooper. 1999. Acute hyperglycemia regulates transcription and post-transcriptional stability of PKC β II mRNA in vascular smooth muscle cells. *FASEB J.* 13). As seen in Figure 31, 2-DOG (25mM) destabilized PKC β II mRNA.




Figure 31. Effect of glucose metabolites on PKC β II mRNA stability.

Synchronized A10 cells upon re-initiation of the cell cycle by DMEM containing 10% FBS were treated with 5.5mM glucose (lane 1, control), 25mM glucose (lane 2, glucose), 25mM 2-deoxyglucose (lane 3, 2-DOG), 25mM 3-O-methylglucose (lane 4, 3-O-MG) or 5.5mM glucose + 19.5mM mannitol (lane 5) for 4 hours. Total RNA was extracted and 2 μ g of RNA was used to perform RT-PCR analysis. The first strand cDNA synthesized was amplified using a sense primer to the common, C4, domain and antisense primer to the PKC β I exon. The PCR product size was 187 bp for PKC β I; 404 bp for PKC β II and 550 bp for β -actin. 2-DOG and 3-O-MG destabilized PKC β II mRNA while mannitol, the osmotic control did not alter

This suggested that the metabolism of glucose beyond the glucokinase step is not required for the down-regulation of PKC β II mRNA. Next, we studied 3-O-methylglucose (3-O-MG), an analog which can be transported into the cell but not metabolized further.

3-O-Methylglucose (25mM) also destabilized PKC β II mRNA and, to a lesser extent, PKC β I mRNA. These results suggested that further metabolism by the hexose monophosphate shunt was not involved. Furthermore, glucose need not be phosphorylated to bring about its effect, thereby eliminating the regulation by hexokinase in PKC β II gene expression. The levels of PKC β I and - β II mRNA remained unchanged with mannitol treatment, the osmotic control.

New protein synthesis is not required for destabilization of PKC β II mRNA by glucose

Even though glucose effects on PKC β II destabilization were detected in 2 hours, it was still possible that a new protein was expressed in response to glucose. To investigate this, synchronized A10 cells (achieved by serum starvation as described in methods) upon re-initiation of the cell cycle with DMEM containing 10% FBS, were treated with 5.5mM glucose (normal glucose), 25mM glucose, or pre-incubated with 20mM cycloheximide for 30 min followed by the addition of 25mM glucose. High glucose destabilized PKC β II mRNA in the presence of cycloheximide indicating that glucose did not signal the synthesis of a new protein but likely activated a protein already present in the cytosol (Table 5) (Figure 32).




Figure 32. Effect of cycloheximide on glucose-induced PKC β II destabilization.

Synchronized A10 cells upon re-initiation of the cell cycle with DMEM containing 10% FBS were pre-incubated for 30 minutes with 20mM cycloheximide followed by the addition of glucose. Total RNA was isolated and RT-PCR was performed on 2 μ g of RNA. The first strand cDNA synthesized was amplified using a sense primer to the common, C4, domain and antisense primer to the PKC β I exon. The PCR product size was 187 bp for PKC β I; 404 bp for PKC β II and 550 bp for β -actin. Lane 1: 5.5mM glucose, control cells; lane 2: 25mM glucose and lane 3: 25mM glucose + cycloheximide. Cycloheximide did not block the ability of glucose to destabilize PKC β II mRNA.

An inhibitor of translation such as cycloheximide induces a rapid stabilization of the message (Ross, 1995, pp.423-450). Since cycloheximide did not alter the glucose-induced destabilization by glucose, it suggests that this process is independent of translation.

Kinase inhibitors implicate a PKC-dependent pathway

Inhibitors of various kinases were used to elucidate the cascade of events involved in the glucose-mediated destabilization of PKC β II mRNA. The choice of concentrations

used and the incubation times were based on previous observations. Phosphatidylinositol 3-kinase (PI 3-kinase) is a mediator of transmitting signals from upstream activators to downstream targets like PKC family (Palmer *et al.*, 1995a, pp.22412-22416), p70-S6 kinase (Chung *et al.*, 1994, pp.71-75), glucose transporter GLUT4 (Hara *et al.*, 1994, pp.7415-7419), serine/threonine kinase Akt/Rac (Franke *et al.*, 1998, Ridley *et al.*, 1992, pp.401-410). To determine the possible involvement of PI 3-kinase, synchronized A10 cells were pre-incubated for 30 minutes with LY 294002 (20 μ M), a specific inhibitor of PI 3-kinase prior to high glucose treatment. The inhibitor interfered with the destabilizing effect of high glucose indicating the possible involvement of a PI 3-kinase-dependent downstream kinase pathway (Table 5).

Table 5. Effect of Inhibitors of several signaling pathways.

INHIBITOR	TARGET	N VALUE	PERCENT OF PKC β II MRNA POST-GLUCOSE TREATMENT
None (5.5mM glucose control)	NA	6	100%
None + Glucose (25mM)	NA	6	5%
Glucose + Cycloheximide (20mM)	Protein synthesis	5	10%
Glucose + LY 294002 (20 μ M)	PI 3-kinase	6	90%
Glucose + CG 41251 (5 μ M)	PKC isozymes	5	100%
Glucose + PD 98059 (20 μ M)	MEK	5	5%
Glucose + AG-490 (5 μ M)	JAK	5	5%
Glucose + Rapamycin (1 μ M)	p70/85 S6 kinase	5	5%
Glucose + Herbimycin A (1 μ M)	Tyrosine kinase	5	90%

To further target downstream pathways involved in PKC β II destabilization by high glucose, synchronized A10 cells were pre-incubated with CG 41251 (5 μ M), a PKC inhibitor, PD 98059(20 μ M), a MAP kinase kinase (MEK) inhibitor, AG-490 (5 μ M), a Janus kinase (JAK) inhibitor, Rapamycin (1 μ M), inhibitor of p70/85 S6 kinase signaling pathway or herbimycin A (1 μ M), a tyrosine kinase inhibitor. Following re-initiation of the cell cycle with DMEM containing 10% FBS, inhibitors were added to synchronized A10 cells 30 minutes prior to the addition of 5.5mM glucose (control) or 25mM glucose (glucose-treated) or 25mM glucose in addition to the inhibitors. The PKC inhibitor CGP 41251, blocked the action of glucose on PKC β II mRNA destabilization. Hence, PKC could phosphorylate the components involved directly or the process involved protein kinases that require phosphorylation by PKC. Results also indicated the potential involvement of a tyrosine kinase-dependent pathway since herbimycin A also prevented PKC β II mRNA destabilization by high glucose. The process was unlikely to be dependent of the MAPK cascade, JAK kinase or p70/85 S6 kinase pathways (**Figure 11**) since their putative inhibitors did not block the effects of high glucose.

Involvement of a reversible phosphorylation process

Extracellular effectors regulate a large number of biological processes by protein phosphorylation-dephosphorylation as an important component of signal transduction cascades. Regulation of cellular functions like gene expression, cell proliferation and differentiation is controlled by a balance between protein kinases (that phosphorylate the substrate) and protein phosphatases (that dephosphorylate) (Jia, 1997, pp.17-26; Barford,

1996, pp.407-412). To further test if phosphatases played a role in this process, okadaic acid (20nM), a potent inhibitor of protein phosphatase PP-2A and PP-1 was added to synchronized A10 cells 30 minutes prior to the addition of either 5.5mM or 25 mM glucose. Okadaic acid interfered with ability of glucose to destabilize PKC β II mRNA indicating that the process may be regulated by phosphorylation/dephosphorylation (Figure 33).




Figure 33. RT-PCR analysis of PKC β I and - β II mRNA after okadaic acid treatment.

Synchronized A10 cells upon re-initiation of the cell cycle with DMEM containing 10% FBS were pre-incubated for 30 minutes with 20nM okadaic acid followed by the addition of glucose. Total RNA was isolated and RT-PCR was performed on 2 μ g of RNA. The first strand cDNA synthesized was amplified using a sense primer to the common, C4, domain and antisense primer to the PKC β I exon. The PCR product size was 187 bp for PKC β I; 404 bp for PKC β II and 550 bp for β -actin. Lane 1: 5.5mM glucose, control cells; lane 2: 25mM glucose and lane 3: 25mM glucose + okadaic acid. Okadaic acid interfered with the ability of glucose to destabilize PKC β II

Expression of a p β G-PKC β II stability reporter system

To demonstrate whether PKC β II specific exon encoded crucial elements that could confer instability in response to high glucose to other genes, a heterologous chimeric minigene was established. The 404 bp PKC β II cDNA amplified by RT-PCR, using the sense primer to the upstream PKC β common C4 domain and the antisense primer to the β IV5 domain, resulted from the 216 bp β IV5 exon inclusion. This PKC β II cDNA was cloned into the p β G vector (kindly provided by N. P. Curthoys, Colorado State University) that encodes a chimeric β -globin/growth hormone mRNA (see Figure 34). The β -globin coding sequence within the parent p β G vector was followed by a multi-cloning site containing four unique restriction sites, into which the PKC β II cDNA was subcloned in frame at the *SpeI* and *XbaI* sites thereby maintaining the 3'UTR and poly(A) tail of the growth hormone.

The resulting chimeric minigene p β G-PKC β II was transiently transfected into human aorta smooth muscle cells. The parent vector, p β G, produced a β -globin mRNA whose levels remained unaltered by glucose concentrations as determined by RT-PCR analysis (Figure 35). Following acute exposure of 3 hours with high glucose (25mM), an 80% decrease in β -globin mRNA in the AoSMC cells transfected with p β G-PKC β II minigene as compared to incubation with normal (5.5mM) glucose was observed.




Figure 34. The pβG-PKCβII chimeric minigene.

The parent pβG vector (6.3 kb) contains a chimeric β-globin/growth hormone gene. The promoter derived from the Rous sarcoma virus long terminal repeat (RSV-LTR) is followed by the transcription start site, the coding sequence (open boxes), and two introns (closed boxes) from the rabbit β-globin genomic DNA. The multi-cloning site (MCS) contains four unique restriction sites into which the PKCβII cDNA was subcloned in frame with the β-globin coding region, at the *Spe I* and *Xba I* sites. The 3' untranslated region and polyadenylation site of the bovine growth hormone cDNA (bGH-pA) is maintained. It also contains genes that direct eukaryotic cell resistance to neomycin (Neo) and bacterial resistance to ampicillin (AMP).

As demonstrated by the RT-PCR analysis, Figure 35, the levels of β -actin mRNA remained constant in both control and glucose-treated AoSMC and A10 cells transfected with p β G-PKC β II stability reporter system. Thus, the introduction of the PKC β II cDNA in a reporter system was sufficient for its down-regulation by exogenous high glucose.




Figure 35. The p β G-PKC β II chimeric minigene is destabilized by high glucose.

The parent vector p β G and p β G-PKC β II minigene were transfected into human aorta smooth muscle cells. Following acute exposure of three hours with high glucose, total RNA was extracted. RT-PCR was then performed on 2 μ g of RNA using sense and antisense primers for the β -globin coding region. The PCR product size was 310 bp for β -globin and 550 bp for β -actin. Lane 1: 5.5mM glucose, control cells; lane 2: 25mM glucose. High glucose did not affect the p β G transfected cells.

Acute exposure to high glucose destabilizes p β G-PKC β II minigene

To further characterize the instability element, half-life determinations were carried out in the presence of 5,6-dichloro-1- β -D-ribofuranosylbenzimidazole (DRB) to




Figure 36. Half-life analysis of p β G-PKC β II mRNA.

The p β G-PKC β II minigene was stably transfected into A10 cells. 50 μ g/ml DRB in 95% ethanol was added to the plates and the 0-hour RNA sample was isolated. 25mM glucose was added to the cells or the cells were maintained in 5.5mM glucose. RNA samples were isolated at 1h, 2h and 6 hours. 10 μ g of total RNA was analyzed by Northern blotting. The graph depicts the mRNA levels remaining at various times after addition of DRB. Blot and graph represents an experiment repeated on 5 different occasions.

inhibit transcription via RNA polymerase II. A10 cells stably transfected with the p β G-PKC β II stability reporter system and the parent vector, p β G were incubated with DRB and incubated with normal or high (5.5mM or 25mM) glucose over a period of 6 hours. Northern blot analysis indicated that the β -globin mRNA of p β G-PKC β II transfected A10 was destabilized within the first 6 hours by high glucose exposure. No changes in the β -actin mRNA levels were observed between normal and high glucose as seen in Figure 36. In the presence of 25mM glucose it appears that the mRNA destabilization involves shortening of the mRNA presumably via deadenylation.

Cytoplasmic extracts from glucose-treated A10 cells contain a protein that binds to the PKC β II mRNA causing its destabilization

Our earlier work with RNA stability assays, had indicated that a nuclease activity involved in PKC β II mRNA destabilization, was present in the cytosolic extract of glucose-treated A10 cells. To ascertain if cytoplasmic extracts from glucose-treated A10 cells contain *trans-acting* factors which could bind to the cis-elements of PKC β II mRNA, an *in vitro* transcription vector was produced by cloning PKC β II cDNA into the pCR-Blunt vector (Invitrogen), upstream of a T7 promoter (Figure 38). A full length transcript of PKC β II cDNA was *in vitro* transcribed as described in methods and used in the band shift assays. RNA-protein complex was observed when the labeled RNA probes were incubated with cytoplasmic extracts of glucose-treated A10 cells, binding reaction carried out as described in methods. No complex formation was observed with the control cytoplasmic extracts as shown in (Figure 39).

To determine if this RNA-protein complex showed specific binding, excess cold competitor RNA probes were added. Binding was eliminated by the specific RNA probes while the non-specific RNA probe did not compete for protein binding.




Figure 37. Schematic of the RNA probes used for the RNA EMSAs.

RNA probes A to E and the restriction enzyme cleavage sites used for their generation by T7 RNA polymerase are indicated. Probe A represents the 404 bp PKC β II exon included mRNA and was prepared by linearization with BamH I. Probe B was linearized at 175 bp with Bgl II, probe C was linearized at 137 bp with Hpa I, probe D was linearized at 102 bp with Ssp I while probe E was linearized at 45 bp with Fok I.




Figure 38. RNA electrophoretic mobility shift assay using full length PKC β II mRNA probe.

³²P labeled RNA probe A was incubated with 3 μ g of cytoplasmic extracts from control cells or glucose-treated cells. The complexes were separated on a 10% polyacrylamide gel, dried and exposed to a Molecular Dynamics Phosphoimaging Screen. RNA-protein binding complexes were observed (black arrows) with glucose-treated A10 cells which was competed out by specific excess unlabeled competitors. Non-specific competitor did not compete for the binding. No binding was observed with BSA. The experiment is representative of results obtained on five separate occasions.

Glucose-regulated instability element is present within the PKC β II exon

To further target the site of sequences involved in the glucose-induced destabilization of PKC β II mRNA, restriction digestion of the PKC β II transcript cloned into pCR-blunt vector was performed to generate deletion constructs as described in Figure 38. RNA gel shift analyses were carried out with probes B, C, D or E incubated with glucose-treated or control cytoplasmic extracts from A10 cells.

RNA-protein binding was observed in glucose-treated cytoplasmic extracts from A10 cells using probe B (Figure 39) which was linearized at 175bp with BglII within PKC β II exon such that the PKC β I-specific exon was eliminated. This RNA-protein binding was competed out with excess of the cold RNA probe B.

No complex formation was observed with RNA probes C (which was linearized at 137bp with HpaI which cut within the PKC β II-specific exon) incubated with cytoplasmic extracts from A10 cells (Figure 40). Probes D (linearized at 102bp with SspI which cut within the PKC β II-specific exon) and E (linearized at 45bp with FokI which cut within the C4 exon) did not show complex formation (data not shown).

This indicated that the putative glucose-regulated instability element was deleted in probes C, D and E, and hence the sequence with protein-mRNA binding activity may lie between the BglII site (at position 175) and HpaI site (at position 137) within the PKC β II-specific coding region.




Figure 39. A cytosolic factor binds to a glucose-regulated element present in the PKC β II coding region.

³²P labeled RNA probes B were incubated with 3 μ g of cytoplasmic extracts from control cells or glucose-treated cells. The complexes were separated on a 10% polyacrylamide gel, dried and exposed to a Molecular Dynamics Phosphoimaging Screen. RNA-protein binding complexes were observed (black arrows) with glucose-treated A10 cells using probe B, which was competed out by specific excess unlabeled competitors. No binding was observed with BSA. The experiment is representative of results obtained on five separate occasions.

BSA
Control
Glucose
Competitor






Figure 40. No RNA protein binding observed using RNA probe C.

UV cross-linking detected association of proteins

To provide an insight to the proteins that bind to the PKC β II mRNA in response to high glucose exposure, ultraviolet cross-linking experiments were performed using probes A and B that demonstrated specific binding. The binding reaction was set up as described for the RNA shift assays and subjected to UV light to generate covalent bonds between RNA and the associated proteins. The samples were digested with RNase A and separated by SDS-polyacrylamide gel

electrophoresis. A small (~10-14kD) protein-RNA binding complex was observed (Figure 41) in glucose-treated cytoplasmic extracts from A10 cells.




Figure 41. UV cross-linking analysis of the RNA-protein binding complex.

³²P labeled RNA probes A and B were incubated with 3 µg cytoplasmic extracts from control cells or glucose-treated A10 cells. The unbound RNA was digested with RNase T1 and then exposed to UV radiation. The proteins were resolved by electrophoresis on a SDS-polyacrylamide gel. Gels were dried and exposed to Molecular Dynamics Phosphoimaging Screen. A 10-14 kDa protein was observed to bind to probes A and B in glucose-treated extracts. The experiment is representative of results obtained on five separate occasions.

DISCUSSION

In this study, several molecular mechanisms by which glucose may regulate PKC β I and - β II gene expression in VSMC were investigated. The elucidation of this regulatory phenomenon is essential since the depletion of PKC β II levels in response to acute hyperglycemia can accelerate cellular proliferation, which may be directly involved in the development of occlusive atherosclerotic lesions. This may occur in addition to the well studied phenomenon of PKC β II activation associated with chronic exposure (10 days to 4 months) of hyperglycemia.

Glucose regulation of PKC β gene expression in VSMC may occur at transcriptional, post-transcriptional, translational, or post-translational levels. The potential sites of regulation included repression of transcription, improper nuclear export of PKC β II mRNA, post-transcriptional mRNA destabilization, decreased translation or multiple effects culminating in decreased PKC β II protein levels. PKC β II protein levels declined sharply by 6 hours of high glucose exposure while PKC β I protein levels did not change significantly between high and normal glucose conditions. Since protein levels often reflect the amount of mRNA transcribed, steady state levels of PKC β mRNA were determined. A decrease in PKC β (I+II) mRNA levels observed in A10 cells exposed to high glucose was likely due to the down-regulation of PKC β gene expression.

Since PKC β I and PKC β II share a common DNA promoter, transcriptional processing of PKC β in VSMC was examined to determine if high glucose down-regulated PKC β gene expression by repressing promoter activity. Transactivating factors, which interact on the *cis*-elements located in the common promoter region of PKC β gene,

could positively or negatively regulate the PKC β pre-mRNA splicing in response to high glucose. It was possible that glucose affected transactivators to preferentially process PKC β pre-mRNA splicing to PKC β I mature mRNA. Transcriptional processing of PKC β in VSMC was first examined to determine if high glucose down-regulated PKC β II mRNA levels by repressing promoter activity. Hyperglycemic conditions, however, only quenched activities of PKC β promoter constructs rather than repress promoter activity. An example is quenching exerted by the yeast factor GAL80, which inhibits gene activation by the positively acting GAL4 protein in the galactose regulation of yeast.

This transcriptional effect accounted for only a fraction of the effect of glucose on PKC β I and PKC β II protein levels. Although promoter activities of construct A(-4.1kb to +179CAT) and construct C(-674 to +179CAT) were decreased by high glucose, promoter activity of construct D (-411 to +179CAT) showed maximum quenching in high glucose. Construct E showed no quenching by high glucose indicating that a potential carbohydrate response element was deleted. Quenching involves the inhibitor interfering with the ability of the activator's activation domain to stimulate transcription. Quenching of transcriptional activity accounted for only a fraction of the effect of high glucose on PKC β I and PKC β II protein levels.

Various positive and negative regulatory *cis*-elements have been identified on the PKC β gene. TATA box (-530) and CAAT box (-395) are found in the reverse order upstream from the transcription start site, with TATA box position towards 5' end. The distant positions of TATA box and CAAT box from the transcription start site indicated involvement of other regulatory elements for promoter activity. Other *cis*-acting

regulatory elements including octamer binding motif, AP₁, AP₂, SP1 binding sites and E boxes were also identified. The 5' region is also rich in CG bases. Construct E, containing -111 to +43 sequence, was sufficient for basal promoter activity indicating that neither the TATA box nor CAAT box is essential for promoter activity. One possibility of quenching of promoter activity may be through the AP₁ binding site, which has been shown to act as a repressor (Benbow *et al.*, 1997, pp.519-526), present at -442 bases upstream of transcription start site. However, construct D (-411 to +179) in which the AP₁ binding site has been deleted, showed maximum quenching in the presence of high glucose indicating that some other mechanism is probably involved in the quenching of PKC β promoter by glucose.

It is possible that glucose may be exerting its quenching effect through a response element located upstream of the transcription start site. First, a carbohydrate response element (ChoRE) that mediates its action via glucose is known. Second, the consensus sequence, 5' CACGTG 3', has been described in the promoter region of a number of glucose responsive genes including L-PK and S-14 in hepatocytes. Third, CACGTG motif is also the core-binding site for the c-Myc family of transcription factors. Fourth, multimers of the ChoREs of either L-PK or S-14 genes can function independently to support the glucose response. Fifth, multiple copies of CACGTG motif are found in the region upstream of the transcription initiation site of the PKC β promoter region at positions -318 and -226 with one or two mismatches.

It is therefore likely that glucose plays a role as a quencher of positively acting regulatory factors by binding to or otherwise activating a ChoRE. Construct D contains a

ChoRE motif in proximity to the CAAT box and AP₂ binding site (TATA box and AP₁ binding site have been deleted). The ability of a bound *trans-acting* factor to stimulate transcription via its activation domain could be inhibited by quenching of the activation domain by glucose which can either bind to *trans-acting* factors without binding to DNA or bind to a site adjacent to the *trans-acting* factor (Latchman, 1995, pp.239-278). This may be a possible explanation for the quenching of PKC β promoter observed in the presence of high glucose.

Since the extent of quenching of the PKC β promoter activity by high glucose varied at different times, simultaneous cell cycle progression studies were performed. Results indicated that PKC β II levels “cycled” with synchronized A10 cells during the 24 hour period of re-initiation of cell proliferation by serum addition. In the presence of high glucose, PKC β promoter activity was down regulated at 14 hours (S phase) compared to the up-regulation of promoter activity following G1 phase in normal glucose. Simultaneous [³H]-thymidine uptake studies indicated an increase in the percentage of cells going through S phase following high glucose exposure. A possible explanation for this effect is that PKC β II may function as a “gate-keeper” for DNA synthesis, with increased PKC β II levels attenuating DNA synthesis in VSMC. In the presence of high glucose, the down-regulation of PKC β II allows for more cells to enter S phase. This increased rate of DNA synthesis accounts for the acceleration of proliferation of VSMC. Thus, in hyperglycemic conditions, the down regulation of PKC β II coincides with increased proliferation of VSMC as shown here.

We further investigated whether high glucose affected the post-transcriptional processing of PKC β transcripts since quenching of PKC β promoter activity, however, did not fully explain the reduction in PKC β mRNA levels. A10 cells exposed to high glucose showed a decrease in PKC β (I+II) mRNA stability within 2 hours in the presence of actinomycin D (an inhibitor of RNA polymerases), indicating an increase in message degradation was also occurring.

Further, the *in vitro* stability assay demonstrated the induction or activation by glucose of a nuclease activity involved in the destabilization of PKC β II mRNA. This divalent cation-dependent nuclease activity was distinct from cyclizing RNases and acid lysosomal RNase since its activity was inhibited by EDTA. Although it was not possible to exclude the presence of potential lysosomal RNase in the reaction completely, the functional role for this enzyme was eliminated by the observation that the degradation of the transcript required divalent cations. This requirement of divalent cations is the hallmark of ribonucleases that regulate mammalian mRNA turnover.

To confirm that glucose specifically destabilized the PKC β II mRNA isoform, RT-PCR was performed with primers that amplified both PKC β I and PKC β II mRNA simultaneously. High glucose destabilized PKC β II mRNA while PKC β I mRNA was not affected significantly. Since the mature PKC β II mRNA is generated by exon inclusion and both PKC β I and PKC β II transcripts contain the PKC β I exon and share a common 3'UTR, the destabilizing elements appear to be introduced within the PKC β II exon or be introduced around the 5' splice site between the exons. Although stability determinants have been described within the mRNA coding regions of genes like *c-myc* is the first

report of a instability element present within an exon that is regulated by glucose. This is a novel observation since the destabilization elements regulated by glucose occur within the PKC β II exon rather than in the 3'UTR of PKC β II mRNA.

The studies were extended to human aortic smooth muscle cells (AoSMC) and it was demonstrated that glucose induced PKC β II destabilization in primary human cell cultures. The combined effects of high glucose on transcriptional quenching of the PKC β promoter and specific destabilization of the PKC β II transcript account for the 60-75% reduction of PKC β mRNA levels observed under steady state conditions in rat and human proliferating aortic smooth muscle cells. The human primary cultures further underscore the physiological relevance of acute high glucose effects on vascular smooth muscle cell proliferation.

In other studies, we used CGP53353 a PKC β II-specific inhibitor, to demonstrate that CGP53353 inhibits glucose-stimulated rat VSMC proliferation (Yamamoto *et al.*, 1998b, pp.205-216). These studies confirmed that PKC β II attenuates cell proliferation and predicts that cells expressing PKC β II are more differentiated and less likely to undergo apoptosis. This could provide an explanation towards the observation that vascular smooth muscle cells overexpressing PKC β II are found in the microvasculature of diabetic rats subjected to untreated hyperglycemia for 2 to 4 months.

Here, we studied the effects of high glucose on PKC β I and PKC β II mRNA on synchronized VSMC during the first cell cycle post-synchronization and demonstrated that glucose-induced destabilization of PKC β II mRNA occurs during the course of the

cell cycle. Also, instead of PKC β II, the PKC β 2 nomenclature has been used on occasions which would imply that PKC β I was the isoform increased by hyperglycemia.

In none of these studies reflected in the prior art were PKC β mRNA levels examined within acute glucose exposure. Our present studies examined the regulation exerted by acute glucose exposure on the PKC β gene and have shown that glucose acted both transcriptionally and post-transcriptionally, with the latter effect accounting for the majority of the down-regulation of PKC β II mRNA.

It was crucial to investigate the mode of glucose action and elucidate potential pathways involved in glucose-induced destabilization of PKC β II mRNA in VSMC. Insulin regulates the alternative splicing of PKC β II mRNA in rat skeletal muscle cells and hence it was essential to investigate the involvement of insulin signaling in the post-transcriptional regulation of PKC β II mRNA by glucose in VSMC. In human aorta smooth muscle cells, glucose destabilizes PKC β II mRNA and not PKC β I mRNA, while insulin did not destabilize PKC β I or - β II mRNA. This implies that the destabilization of PKC β II mRNA by glucose is distinct from the regulation of insulin-induced alternative splicing of PKC β II mRNA. Since insulin enables the uptake of glucose for efficient metabolism in the cell, the implication is that buildup of free glucose in the cytosol may be essential for glucose-induced destabilization of PKC β II mRNA.

Studies with the PKC inhibitor showed that a PKC-dependent pathway may be associated with the destabilization of PKC β II mRNA by high glucose. Insulin is known to activate PKC in VSMC. The finding that insulin did not destabilize PKC β II mRNA suggests that a different activation mechanism may be involved. The PKC inhibitor used

here, CGP41251, is not specific for a single PKC isoform. This could imply the presence of a cross-talk between PKC isoforms similar to that between PKC α and PKC δ . They demonstrated that activated PKC α up-regulated the steady-state levels of PKC δ mRNA, which caused an increase in the PKC δ protein level. Protein kinase C is a mediator of signal transduction pathways that alter gene expression. Activation through a PKC-dependent pathway, of transcription factors like AP-1 can be altered by tumor-promoting phorbol esters like 12-O-tetradecanoylphorbol-13-acetate (TPA). For instance, PKC activation by TPA destabilizes PKC δ mRNA via a PKC-dependent pathway in A20 cells.

Using glucose analogs, we showed that glucose need not be metabolized further by glucokinase nor activate the hexose mono-phosphate shunt or the hexosamine biosynthetic pathway. Glucose could destabilize PKC β II mRNA in VSMC without any modification even though it is predominantly present as glucose-6-phosphate in the cell.

Cycloheximide did not block destabilization of PKC β II mRNA by high glucose indicating that de novo protein synthesis is not required. Further, it is known that mRNA half life is linked to translation. Inhibition of translation by cycloheximide results in stabilization of mRNA. Since cycloheximide does not interfere with glucose-induced destabilization of PKC β II mRNA, it suggests that the regulation is independent from translation.

Okadaic acid inhibited the destabilization thereby implying that serine/threonine phosphatases like PP-2A and PP-1 are involved in regulating the process. An inhibitor of PI3-kinase blocked the destabilization of PKC β II mRNA by high glucose implying the involvement of a downstream target of PI3-kinase such as PKC. Further, the lack of

effect of inhibitors for the MAPK cascade, JAK kinase or p70/85 S6 kinase suggests that these pathways are not involved in high glucose-induced PKC β II mRNA destabilization in VSMC.

Since acute hyperglycemia destabilized PKC β II mRNA and PKC β I mRNA levels remaining unaltered, it was possible that the putative glucose-responsive instability element resided within the exon encoding PKC β II mRNA. The PKC β II cDNA was cloned into the pCR-blunt vector and its sequence was determined. Restriction digestion and sequencing confirmed that the mature PKC β II mRNA was generated by inclusion of the 216 bp exon.

A heterologous stability reporter system was established in vascular smooth muscle cells to demonstrate that PKC β II exon contains a instability element regulated by high glucose. The chimeric p β G-PKC β II minigene comprises of the parent p β G vector into which the PKC β II cDNA was subcloned in frame with the β -globin exon into the multi-cloning site. p β G vector is a chimera of β -globin/growth hormone such that the multi-cloning site is followed by the 3'UTR and polyadenylation site of the bovine growth hormone. This parent vector was an appropriate choice since the 3'UTR and poly(A) tail, which are common to both PKC β I and - β II mRNA, are eliminated as the determinants of stability. β -globin mRNA was destabilized by acute hyperglycemia in the p β G-PKC β II stably transfected human aorta smooth muscle cells while the β -globin mRNA in the p β G stable transfectants were not affected by extra-cellular high glucose concentrations. This has two implications: (i) the PKC β II cDNA contains a glucose-responsive instability element within its exon; and (ii) the 3'UTR and poly(A) tail - the

common determinants of mRNA stability, are not involved in glucose-mediated destabilization of PKC β II mRNA in VSMC. This chimeric gene contains the PKC β II cDNA (404 bp exon) subcloned in frame with the β -globin. The introns and other 3' flanking sequences of PKC β II mRNA are not present. These sequences could play an important role in secondary structure and could contain stability determinants that act mutually to influence the mRNA stability. These sequences are omitted in the chimeric minigene (p β G-PKC β II), and hence a lesser extent of destabilization is observed. It may be possible that the PKC β I exon that is not translated (due to the introduction of a STOP codon) in the mature PKC β II mRNA could act as a longer 3' UTR thereby affecting its stability.

Half-life analysis of the β -globin mRNA in the p β G-PKC β II stable transfectants, using DRB, indicated that glucose destabilized β -globin mRNA within 2 hours of exposure. DRB was preferred as the inhibitor of transcription by polymerase II since actinomycin D was reported to inhibit translation and inhibit mRNA degradation in some instances. This rapid destabilizing effect of acute hyperglycemic further strengthens the hypothesis that the glucose effect is conferred by the instability element present within the PKC β II exon.

Although chimeric mRNAs provide valuable information regarding the sequences affecting the stability of the mRNA, truncated chimeric mRNAs may give misleading information regarding mRNA stability since factors such as translation rate, secondary structure, and intracellular localization may influence their stability. Further, more than one stability determinant may be present in the mRNA which could be regulate its

turnover. Hence, to identify the instability elements in PKC β II mRNA regulated by high glucose in VSMC, *in vitro* binding interactions between RNA and proteins present in the cytosol were observed by RNA mobility shift assays. Cytoplasmic extracts from glucose-treated A10 cells were incubated with varying lengths of *in vitro* transcribed PKC β II labeled probes. A region between 175bp and 137bp in PKC β II cDNA was identified to contain an element that bound to a protein present in the cytoplasm of glucose-treated A10 cells. This region containing the 38 nucleotides corresponds to positions 2127 bp and 2165 bp of the PKC β II cDNA and occurs within the PKC β II coding region. Interestingly, its position is immediately before the STOP codon of the PKC β II exon. This binding site was in close proximity to a stem-loop structure in the PKC β II mRNA (see Figure 42, Figure 43, and Figure 44 of secondary structure of C-terminal 350bp of PKC β II mRNA with the restriction digestions). Premature stop codons affect mRNA stability as observed in phytohemagglutinin mRNA whose stability is decreased by the presence of premature nonsense codons.

Elimination of RNA-binding by competitor probes demonstrated the specificity of the interaction by the instability element without altering the native RNA. Using UV cross-linking, a 10-14 kD protein was identified as binding to probes A and B. The function of this protein could be similar to that of an endoribonuclease as in the case of transferrin receptor or apolipoprotein or an accessory protein aiding in the endoribonucleatic cleavage. For example, recently Canete-Soler et al (Canete-Soler, R., M. L. Schwartz, Y. Hua, and W. W. Schlaepfer. 1998. Characterization of ribonucleoprotein complexes and their binding sites on the neurofilament light subunit mRNA. J. Biol. Chem. 273:12655-

12661) described a stability region present within a 68-nt sequence, localized between the 3'UTR and the 3'-coding region of the neurofilament NF-L, that serves as the binding site for a unique ribonucleoprotein complex.

Glucose plays an important regulatory role in the expression of PKC β II in VSMC. Acute high glucose could exert regulatory effects through a putative carbohydrate response element located upstream of the PKC β transcription start site and through glucose-induced post-transcriptional destabilization of PKC β II message via a nuclease activity present in the cytosol. In this case, the rate of mRNA degradation plays an important role in establishing levels of gene expression. Although hormones, growth factors and ions are known to induce changes in mRNA stability, here we determined that PKC β II mRNA levels are regulated primarily by mRNA destabilization in response to glucose, a cellular nutrient. This multi-level regulation of gene expression by glucose suggests that PKC β II may play a pivotal role in vascular smooth muscle cell function.

The physiological implications in diabetic patients that suffer from frequent episodes of acute hyperglycemia are profound. Acute hyperglycemia down-regulates PKC β II levels which results in accelerated proliferation of vascular smooth muscle cells and ultimately leading to increased risk of developing atherosclerosis.

In conclusion, this investigation provides molecular insight into the mechanisms involved in the destabilization of PKC β II by high glucose in vascular smooth muscle cells. To our knowledge, this is the first report of identification of instability element present within the PKC β II coding region that is regulated by acute high glucose exposure. The ability of glucose, an important cellular nutrient, to influence mRNA turn-over

within acute exposure in vascular SMC further emphasizes its role in regulation of gene expression.

Conclusion

Detailed description of the invention: The BII-exon should destabilize a cDNA insert in the presence of high extracellular glucose. For our initial studies, the PBglobin (pBG) vector (obtained from Norman P. Curhoys, Colorado State University) was used (2). The chimeric pBG-BII plasmid was constructed by inserting the PKCBII exon and flanking regions as shown below into the vector at a multicloning site. The vector was created by inserting the PvuII-Bgl II fragment of pSVB10, the portions of the first three exons and the two introns of the rabbit B-globin gene, into the HindII site of the pRc/RSV vector. The B-globin genomic sequence extends from 9 bp upstream of the transcription initiation site to the translation stop codon. pBG contains a strong viral promoter derived from the long terminal repeat of the Rouse sarcoma virus followed by genomic DNA containing the transcriptional start site, the 3' nontranslated region, the full coding sequence and two introns of the rabbit B-globin gene, a MCS with four restriction sites, and the 3'nontranslated region and polyadenylation site of the bovine growth hormone gene. Other chimeric constructs will also be tested such as CAT and luciferase to validate the effect of the BII exon (3). The minimal region of the sequence will be used in tetracycline repressor construct systems (4). The chimeric reporter constructs are tested in a number of cell types. We have found that glucose destabilizes PKCBII mRNA in L6 rat skeletal muscle cells, rat aortic cells, PC12 cells, and other tumorigenic and normal cell lines will also be tested for the ability of glucose to destabilize to chimeric construct.

To further define the minimal boundaries of the *cis*-elements, a portion of the 3' region of the PKCBII mRNA as diagrammed above was obtained as a 404 bp insert containing the entire 216 bp BII exon and 3' and 5' sequences from the flanking common and BI exon (4). This insert will be restricted by deletion mutagenesis to further limit the amount of mRNA necessary for destabilizing genes of interest.

The *cis*-acting elements destabilizing mRNA in response to high extracellular glucose were identified by several criteria in the exon encoding the C-terminal 52 amino acids for PKCBII and are shown in Figure 45. The PKCBII-specific exon is inserted into mature mRNA via alternative splicing of pre-mRNA. The elements inserted may form stem-loop structures providing the secondary structure recognized by destabilizing endonuclease-protein complexes that break A-T bonds (1).

Analysis of PKCBII exon sequences reveals multiple potential *cis*-acting elements that may be involved in the destabilization of the PKCBII sequence. These elements may form stem-loop structures that are recognized by putative carbohydrate response-acting factors to target the sequence for decay by cytosolic endonucleases (1).

Figure 46 sets forth an exemplary sequence.

Throughout this specification a variety of references have been cited, each of which is herein incorporated in its respective entirety.

The many features and advantages of the invention are apparent from the detailed specification, and thus, it is intended by the appended claims to cover all such features and advantages of the invention which fall within the true spirit and scope of the invention. Further, since numerous modifications and variations will readily occur to those skilled in the art, it is not desired to limit the invention to the exact construction and

operation illustrated and described, and accordingly, all suitable modifications and equivalents may be restored to, falling within the scope of the invention. While the foregoing invention has been described in detail by way of illustration and example of preferred embodiments, numerous modifications, substitutions, and alterations are possible without departing from the scope of the invention defined in the following claims.

What is claimed is:

1. A nucleic acid construct for post-transcriptional control of expression of a protein in a eucaryotic cell, wherein said construct encodes an mRNA corresponding to said protein, and said mRNA comprises a metabolite responsive instability element, whereby post-transcriptional stability of said mRNA is controlled by the metabolic substance or an analogue thereof.
2. The construct of claim 1 wherein the metabolite responsive instability element comprises the sequence
TAACTCTGAATTTTAAAACCCGAAGTCAAGAGCTAGTA.
3. The construct as in claim 1 wherein the metabolic substance is glucose, 3-O-methylglucose, 2-deoxyglucose, or combinations thereof.
4. The construct as in claim 1 wherein said nucleic acid is a plasmid.
5. The construct as in claim 1 wherein said nucleic acid is a virus.
6. The construct as in claim 1 wherein said nucleic acid is a retrovirus.
7. The construct as in claim 1 wherein said nucleic acid is a naked DNA.
8. A transgenic animal comprising the construct of claim 1.
9. The animal of claim 8 wherein said animal is a mouse.
10. An antisense nucleic acid or analogue that is complementary to the nucleic acid sequence
TAACTCTGAATTTTAAAACCCGAAGTCAAGAGCTAGTA.
11. An antisense nucleic acid or analogue that is complementary to at least 15 consecutive base pairs of the nucleic acid sequence
TAACTCTGAATTTTAAAACCCGAAGTCAAGAGCTAGTA.
12. A method for controlling expression of a gene in a eucaryotic cell, comprising inserting a metabolite responsive instability element into said gene, whereby post-transcriptional stability of mRNA is controlled by the metabolic substance or an analogue thereof.
13. The method as in claim 12, wherein said metabolite responsive instability element comprises the sequence
TAACTCTGAATTTTAAAACCCGAAGTCAAGAGCTAGTA.
14. The method as in claim 12, wherein said metabolic substance is glucose, 3-O-methylglucose, 2-deoxyglucose, or mixtures thereof.

15. A method for treating vascular disease comprising inserting the construct of claim 1 into at least one cell of a patient.
16. A method for treating cancer comprising inserting the construct of claim 1 into at least one cell of a patient.
17. A method for treating hypertension comprising inserting the construct of claim 1 into at least one cell of a patient.
18. A method for treating atherosclerosis comprising inserting the construct of claim 1 into at least one cell of a patient.
19. A method of screening for mutations of the metabolite responsive instability element of claim 1 comprising:
 - obtaining a DNA sample from a patient; and
 - sequencing said metabolite responsive instability element, and
 - detecting mutations within said metabolite responsive instability element.
20. A recombinant cell comprising the construct of claim 1.
21. A primer comprising a nucleic acid capable of recognizing and binding the metabolite responsive instability element of claim 1.
22. A kit for detecting the metabolite responsive instability element of claim 1, which comprises multiple containers wherein each of the separate containers comprise:
 - a set of primers for PCR detection of said metabolite responsive instability element, and
 - optionally a positive control comprising the metabolite responsive instability element DNA.
23. A nucleic acid probe comprising a DNA sequence having affinity for the DNA sequence of the metabolite responsive instability element of claim 1.
24. A host cell comprising the nucleic acid of claim 1, in which said nucleic acid is isolated and purified.
25. A replicable vector comprising the nucleic acid construct of claim 1.

ABSTRACT OF THE DISCLOSURE

Protein kinase C (PKC) has been implicated as a mediator of diabetes-induced vascular proliferation. This study investigated the regulation of PKC β gene expression following acute glucose exposure in human vascular smooth muscle cells and in A10 cells, a rat aortic smooth muscle cell line. Western blot analysis showed that PKC β II protein levels decreased with high glucose (25mM) while PKC β I levels were unaltered. PKC β mRNA levels were depleted by 60-75% in hyperglycemic conditions. Quenching of PKC β promoter activity by glucose suggested involvement of a carbohydrate response element in the 5' promoter region. Simultaneous cell cycle studies indicated an increase in the percentage of cells going into S phase in high glucose implying that quenching of PKC β transcription may be related to cell cycle progression. It was demonstrated that glucose induced post-transcriptional destabilization of PKC β II message via a nuclease activity present in the cytosol. The specificity of glucose to post-transcriptionally destabilize PKC β II, but not the PKC β I, isoform was confirmed in both A10 cells and primary cultures from human aorta.

To further elucidate the intracellular signaling mechanisms, glucose analogs were used to study the pathways by which glucose acted to destabilize PKC β II mRNA. Glucose-induced destabilization of PKC β II mRNA is independent of the hexosamine or hexokinase pathways. Cycloheximide did not block destabilization of PKC β II mRNA by high glucose indicating that the process is independent of translation. Glucose may act

via PKC signaling pathways and may be regulated by serine/threonine phosphorylation/dephosphorylation.

A heterologous chimeric minigene encoding PKC β II cDNA subcloned into the p β G expression vector comprising the coding sequences of β -globin genomic DNA and 3'UTR and polyadenylation site of bovine growth hormone cDNA was constructed. Half-life analysis indicated a rapid glucose-induced destabilization of β -globin mRNA in p β G-PKC β II transfected cells. Mobility shift analysis indicated the presence of a glucose-responsive instability element within the exon included in the mature PKC β II mRNA in VSMC. UV cross-linking analysis showed a small protein (~10-14 kDa) binding near a stem-loop structure within the PKC β II-specific exon. This is a novel finding of a instability element within the PKC β II mRNA coding region that is regulated by glucose in aorta smooth muscle cell.

Structure: 1 ENERGY = -73.3 PKCh2




Figure 42. PKC β II mRNA sequence and RNA secondary structure analysis.

```

UUUUAAACCA AAAGCUUUUU GGGCGAAACG CUGAAACUUC GACCGGUUUU UCACCCGCCA
UCCACCAAGUC CUAACACCUC CGACCAGGAA GUCAUCAGGA AUUUUGACCA AUCAGAATTC
GAAGGAUUUC CUUUGUUAAC UCUGAAUUUU UAAACCCGA AGUCAAGAGC UAGUAGAUCU
GUAGACCUCC GUCCUUCAUU UCUGUCAUUC AAGCUCACAG CUUCAUGAG AGACAAGCGA
GACACCUCCA ACUUCGACAA AAGUUCACCA GGCAGCCUGU GGAACUGACU CCCACUGACA

```

Structure: 1 ENERGY = -35.4 PKCb2 [175]




Figure 43. PKC β II mRNA sequence linearized at 175 bp with *Bgl II* and RNA secondary structure analysis.

```
UUUAAAACCA AAAGCUUUUU GGGCGAAACG CUGAAACUUC GACCGGUUUU UCACCCGCCA
UCCACCAGUC CUAACACCUC CGACCAGGAA GUCAUCAGGA AUAUUGACCA AUCAGAATTC
GAAGGAUUUC CUUUGUUAAC UCUGAAUUUU UAAAACCCGA AGUCAAGAGC UAGUA
```


Structure: 1 ENERGY = -27.2 PKCb2 (137)





Figure 44. PKC β II mRNA sequence linearized at 137 bp with *Hpa* I and RNA secondary structure analysis.

```
UUUAAAACCAAAAGCUUUUU GGGCGAAACG CUGAAACUUC GACCGGUUUU
UCACCCGCCA UCCACCAGUC CUAACACCUC CGACCAGGAA GUCAUCAGGA
AUAUUGACCA AUCAGAATTC GAAGGAUUUC CUUUGUU
```



TRANSMITTAL

NOV 8 1999

LRR

To: Gianna Arnold
Pepper Hamilton LLP

Fax: 202 220-1665

From: Wendy Davis

Date: November 8, 1999

Pages: 15, including cover

Re: NEW APPLICATION
USF Ref No. 99A010
Glucose regulated mRNA...

CONFIDENTIALITY NOTE: The information contained in this facsimile message may be legally privileged and confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this facsimile message is prohibited. If you have received this facsimile message in error, please immediately notify us by telephone and return the original message to us at the address above via U.S. Postal Service. Thank you.

99-11-08A11:26 RCVD

Wendy Davis
Associate Director
University of South Florida
Patents & Licensing
4202 E. Fowler Avenue
FAO 126
Tampa, Florida 33620-7900
Phone (813) 974-8480
Fax (813) 974-8490
Email wdavis@research.usf.edu

✓ 99A010 CC KGP-3/16/99

APPENDIX 11

CONFIDENTIAL

INVENTION DISCLOSURE FORM
DIVISION OF PATENTS AND LICENSING
UNIVERSITY OF SOUTH FLORIDA
FAO 126

DATE: 3/11/1999

DISCLOSURE NO.: 99A010

INVENTOR SUBMITTING DISCLOSURE: Denise R. Cooper and Niketa A. Patel

TITLE: Associate Professor and Research Post-doc

BUSINESS ADDRESS: VAR 151

E-MAIL ADDRESS: dcooper@com1.med.usf.edu and npatel@com1.med.usf.edu

PHONE NUMBER: (813) 972-2000 X 7017 or X 7883

SIGNATURE: Denise R. Cooper Niketa Patel

TITLE OF INVENTION: Glucose regulated mRNA instability element.

DIRECTIONS:

This form is to be completed and submitted to the Division of Patents and Licensing by any Researcher who believes he or she has developed a new invention. The purpose of this form is to permit the Division of Patents and Licensing to determine whether any legal protection for the invention will be sought. **HENCE IT IS IMPORTANT THAT ALL QUESTIONS BE ANSWERED AS ACCURATELY AS POSSIBLE.**

THE INVENTION

A. What is the problem this invention addresses?

See attached document

B. In the space provided, please briefly describe and explain your invention in the form of an abstract. If the space provided is not sufficient, kindly attach the abstract to this Disclosure Form.

See attached document

Title: Glucose-regulated mRNA instability element**2A. What is the problem this invention addresses?**

Regulatable vectors for gene expression are often not reliable since they can be "leaky". They usually consist of systems where the gene of interest is cloned downstream of a minimal viral promoter fused to copies of the tetracycline operator. The promoters used with these repressor sequences are, however, not totally repressed in many cells. By engineering a construct that is also regulated at the post-transcriptional level, full repression of such a promoter could be achieved in a wider variety of cells. We propose that by inserting instability sequences downstream of an inserted cDNA, genes can be further regulated using high extracellular concentrations of glucose or non-metabolized analogues. Both Tet and Retroviral Tet Systems (Clontech) show promise for regulating transcription of genes in cells. The ecdysone-inducible expression system derived from *Drosophila* is also commercially available (Invitrogen) and may have even lower basal activity in mammalian cells. Basal activity of the tetO.HCMC IE promoter is highly variable when tested in several cell lines. Although the promoter was repressed in HeLa and PC12 cells, basal levels were 10-30 fold higher in BHK cells. This high basal activity limits the use of the tetracycline-repressed promoter. If a construct could be engineered that was also regulated at the post-transcriptional level, full repression of such a promoter could be achieved in a wider variety of cells. There are several inducible promoters available, however, no one has developed a system to regulate gene expression at the post-transcriptional level. The post-transcriptional regulation of mRNA destabilization of a gene is another possibility for designing regulatable gene expression constructs. If the cDNA can be destabilized by a non-toxic nutrient or analogue, then expression can be stabilized when the analogue is withdrawn.

2B: The invention:

The *cis*-acting elements destabilizing mRNA in response to high extracellular glucose were identified by several criteria in the exon encoding the C-terminal 52 amino acids for PKCBII and are shown below. The PKCBII-specific exon is inserted into mature mRNA via alternative splicing of pre-mRNA. The elements inserted may form stem-loop structures providing the secondary structure recognized by destabilizing endonuclease-protein complexes that break A-T bonds (1).




FIGURE 1: Diagram of 3' exons encoding PKCBI and PKCBII via exon inclusion/exclusion and regions of PKCBII exon involved in destabilization of mRNA.

The PKC β gene encodes two isoforms of the serine/threonine kinase that differ by their C-terminal fifty to fifty-two amino acids. If the exon for PKC β II is included in the mature mRNA transcript, PKC β II protein is encoded, the PKC β I exon is not translated due to a stop codon within the exon. If the PKC β II exon is excluded, PKC β I protein is encoded. The 3' untranslated region (UTR) of PKC β I is identical for both PKC β I and PKC β II mRNA. The mRNA for PKC β II is rapidly destabilized in the presence of high extracellular glucose (25 mM) in a number of cells. Like transcription, RNA processing, and translation, mRNA decay is a precise process dependent on specific *cis*-acting sequences and *trans*-acting factors. There are specific pathways triggering mRNA decay including poly (A) shortening, arrest of translation, and endonucleolytic cleavage. We have found that high extracellular glucose concentrations destabilize PKC β II mRNA in a rapid manner, and a nuclease activity in the cytoplasm is involved.

Analysis of the PKC β II exon sequence reveals multiple potential *cis*-acting elements that may be involved in the destabilization of the PKC β II sequence. These elements may form stem-loop structures that are recognized by putative carbohydrate response-acting factors to target the sequence for decay by cytosolic endonucleases (1).

The sequence could be placed down-stream of the cDNA insert to be expressed in cells, and high extracellular glucose or an analog could be maintained in the media to keep the mRNA of interest down-regulated. When expression of the gene is desired, lowering cell glucose levels to normal (5.5 mM) levels would allow for expression of the target mRNA. Conversely, a gene could be rapidly down-regulated by elevating high extracellular glucose. If the destabilization signal sequence were cloned into a plasmid also carrying the tetracycline repressor, it could fine-tune the system to keep basal levels of the gene low. Glucose or a non-metabolizable analogue provides an inexpensive, non-toxic alternative for regulating gene expression as opposed to expensive and potentially toxic antibiotics.


2C. Detailed description of the invention: The β II-exon should destabilize a cDNA insert in the presence of high extracellular glucose. For our initial studies, the p β globin (p β G) vector (obtained from Norman P. Curthoys, Colorado State University) was used (2). The chimeric p β G- β II plasmid was constructed by inserting the PKC β II exon and flanking regions as shown below into the vector at a multicloning site. The vector was created by inserting the PvuII-Bgl II fragment of pSV β 10, the portions of the first three exons and the two introns of the rabbit β -globin gene, into the HindIII site of the pRc/RSV vector. The β -globin genomic sequence extends from 9 bp upstream of the transcription initiation site to the translation stop codon. p β G contains a strong viral promoter derived from the long terminal repeat of the Rouse sarcoma virus followed by genomic DNA containing the transcriptional start site, the 3' nontranslated region, the full coding sequence and two introns of the rabbit β -globin gene, a MCS with four restriction sites, and the 3' nontranslated region and polyadenylation site of the bovine growth hormone gene. Other chimeric constructs will also be tested such as CAT and luciferase to validate the effect of the β II exon (3). The minimal region of the sequence will be used in tetracycline repressor construct systems (4). The chimeric reporter constructs are tested in a number of cell types. We have found that glucose destabilizes PKC β II mRNA in L6 rat skeletal muscle cells, rat aortic vascular smooth muscle cells, and MCF-7 breast cancer cells. Cells such as NIH-3T3 fibroblasts, HeLa cells, PC12 cells, and other tumorigenic and normal cell lines will also be tested for the ability of glucose to destabilize the chimeric construct.

To further define the minimal boundaries of the *cis*-elements, a portion of the 3' region of the PKC β II mRNA as diagrammed above was obtained as a 404 bp insert containing the entire 216 bp β II exon and 3' and 5' sequences from the flanking common and β I exon (4). This insert will be restricted by deletion mutagenesis to further limit the amount of mRNA necessary for destabilizing genes of interest.

- 1. The destabilization of the PKC β II mRNA by high extracellular glucose is specific for PKC β II mRNA, PKC β I mRNA is not destabilized (4). To determine whether glucose or its metabolites destabilized the mRNA, two glucose analogues were tested. 3-O-methylglucose is taken up by cells but not phosphorylated by hexokinase. 2-Deoxyglucose is taken up by cells and phosphorylated but not further metabolized. Both analogues destabilized PKC β II mRNA. Thus, the further metabolism of glucose to glucose-6-phosphate is not required for this effect. This offers another means of regulating mRNA stability of the chimeric construct using glucose analogues.

2D. Drawing of the insert.

Figure 2: Restriction map of 3' region of PKC β II exon with portions of 3'- and 5'-flanking exons to be cloned downstream of the cDNA of interest.

**References:**

1. Patel, N. A., Chalfant, C.E., Yamamoto, M., Watson, J.E., Eichler, D.C., Cooper, D.R. Acute hyperglycemia regulates transcription and post-transcriptional stability of PKC β II mRNA in vascular smooth muscle cells. *FASEB* 13, No. 1: 103-113.
2. Hansen, W.R., Barsic-Tress, N., Taylor, L., Curthoys, N.P. The 3'-nontranslated region of rat renal glutaminase mRNA contains a pH-responsive stability element. *Am. J. Physiol.* 271 (Renal Fluid Electrolyte Physiol. 40): F126-F131, 1996.
3. Amara, F.M., Sun, J., Wright J.A. Defining a novel cis-element in the 3'untranslated region of mammalian ribonucleotide reductase component R2 mRNA. *J. Biol. Chem.* 271: 20126-20131, 1996.
4. Ackland-Berglund, C.E., Leib, D.A., Efficacy of tetracycline-controlled gene expression is influenced by cell type. *Biotechniques* 18: 196-200, 1995.

9900 Ninth Street North
St. Petersburg, FL 33716-3801

(3) the grant or contract number:

9810139FL

(4) the USF grant specialist who helped you obtain the grant:

Meg Damato, Sponsored Research

NOTE: If the research was conducted under research grants from more than one outside sponsor, on a separate piece of paper, please answer question 3B for each outside sponsor.

PUBLICATIONS

A. Has the invention been published?

Yes

No

X

B. If the answer to 4A is yes, please provide the complete citation for the publication including the date of publication:

C. Do you intend to publish the invention?

Yes

No

X

D. If the answer to 4C is yes, please provide the date on which the invention is to be published.

Manuscript in preparation.

E. Have you disclosed, or do you intend to disclose the invention to a scientific or professional association gathering in the form of either an oral presentation or a poster presentation?

Yes

No

X

Please circle the type of presentation: POSTER ORAL

F. If the answer to 4E is yes, please provide:

(1) the name of the scientific or professional organization:

Keystone Symposia

(2) the location of the gathering:

Sante Fe, New Mexico

(3) the date of the gathering:

Feb 23-28, 1999

G. Has the invention been publicly disclosed in any other manner?

Yes X
No

H. If the answer to 4G is yes, please give the date on which the public disclosure was made and a detailed description of the circumstances under which the public disclosure was made:

Dissertation of Niketa A. Patel on November 6th 1998.

5. PRIOR ART

A. Are you familiar with any publications which disclose an invention similar to the invention disclosed in this Invention Disclosure Form?

Yes _____
No X

B. If the answer to 5A is yes, please provide for each publication:

(1) the full title and citation of the publication:

(1) a brief explanation as to why the invention disclosed in this Invention Disclosure Form is an improvement over the invention disclosed in the publication:

[illegible]

(If more space is needed, please use a separate piece of paper.)

6. **INVENTOR(S)**

A. Please state the number of inventors of the Invention disclosed herein:

2

B. For each inventor, please state:

Inventor I

(1) Name:

Denise R. Cooper, Ph.D.

(2) Title:

Associate Professor

(3) Home Address:

4096 40th Street South

(4) City, State, Zipcode:

St. Petersburg, FL 33711

(5) Home Telephone:

813-867-2480

(6) Business Address:

**USF College of Medicine and J. A. Haley Veterans Hospital,
13000 Bruce B. Downs Blvd.**

(7) City, State, Zipcode:

Tampa, FL 33612

(8) Business Telephone:

813-972-2000 X 7017

(9) Citizenship:

.....

Signature: Debra R. Cooper
Date: March 11, 99

Inventor II

(1) Name: **Niketa A. Patel**

(2) Title:
Research Post-doc

(3) Home Address:
13103 A Whitestone Drive

(4) City, State, Zipcode:
Tampa, FL 33617

(5) Home Telephone:
813-985-1453

(6) Business Address:
USF College of Medicine and J. A. Haley Veterans Hospital,
13000 Bruce B. Downs Blvd.

(7) City, State, Zipcode:
Tampa, FL 33612

(8) Business Telephone:
813-972-2000 X 7883

(9) **Citizenship:**
Indian, (US Permanent Resident)

Signature: Niketa Patel
Date: 3/12/99

Inventor III

(1) Name:

-NA-

(2) Title:

(3) Home Address:

(4) City, State, Zipcode:

(5) Home Telephone:

(6) Business Address:

(7) City, State, Zipcode:

(8) Business Telephone:

(9) Citizenship:

Signature: _____

Date: _____

Inventor IV

(1) Name:

-NA-

(2) Title:

(3) Home Address:

(4) City, State, Zipcode:

(5) Home Telephone:

(6) Business Address:

(7) City, State, Zipcode:

(8) Business Telephone:

(9) Citizenship:

Signature:

Date:

NOTE: If there are more than four inventors, please attach additional sheets for each inventor not named here. If the inventions are described in a publication which identifies authors other than the inventors, please describe the contributions made by the non-inventors.

99A010

5